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Abstract
Background
Human milk is considered the best source of nutrition for all newborns as it contains
important growth, developmental and immunological factors. The WHO (2003)
recommends exclusive breastfeeding for the first six months of age, with
complementary breastfeeding up to two years and beyond. However, some women
experience complications of the breast that lead to early cessation of breastfeeding,
which can adversely affect the well being of the developing infant and her own health.
Nipple pain is the most commonly cited reason for weaning in the first week post
partum. Nipple pain is also linked to mastitis from milk stasis and possible bacterial
infection, although the influence of bacteria is still largely unknown. However, it is
known that the presence of bacteria and fungi along with their metabolites contribute
to the composition of the milk as the baby receives it.
Metabolomics is increasingly being utilised in the dairy industry to determine
spoilage as a result of teat trauma and mastitis. Given the current diagnostic
application of metabolomics in clinical medicine uses blood and urine samples, it has
been proposed as a potential tool for detecting biomarkers and determining
compositional changes in human milk. Measuring the composition of milk from
human mothers experiencing persistent nipple pain, with or without evidence of
trauma, and identifying the influence of this condition on endogenous and exogenous
metabolites may determine the relationship between milk composition and nipple
pain.
Aims
The aims of this study were to source the appropriate human and bovine milk
samples; to identify and quantify bacterial and fungal species using traditional culture
and microscopy techniques; to measure the effect of nipple pain on the paracellular
pathway of the breast by measuring the sodium and potassium concentration and ratio
in the milk; to optimise GC-MS methodology for the measurement of milk
metabolites; and to use untargeted metabolomics to identify compositional differences

xvii

in the metabolite profile in human milk from mothers presenting with nipple pain
compared to healthy control mothers.
Results
Two groups were recruited; a control group of mothers not experiencing nipple pain
(n=22 samples) and a group of mothers experiencing persistent nipple pain during
breastfeeding (n=11 samples); mothers with unilateral nipple pain supplied a milk
sample from their affected and non-affected breast (n=4). The nipple pain group
(n=11) was divided into two subgroups; persistent nipple pain without evidence of
trauma (PG) (n=6) and persistent nipple pain with evidence of trauma (TG) (n=5).
Additionally 9 bovine samples were collected, 3 from healthy cows (control), 4 from
cows presenting with mastitis and 2 from a single storage vat, to be used as positive
controls throughout the study.
All 42 samples were tested for the presence of microbial and fungal species, sodium
and potassium concentrations and ratio were determined and untargeted metabolomics
analysis of the milk metabolome was performed.
Overall there was no significant difference in microbe content between the human
control and nipple pain group (1, 623 CFU/ml vs. 1, 503 CFU/ml); the TG subgroup
had the highest colony count of 2, 778 CFU/ml. The bovine mastitis group had a
higher colony count than the bovine control group, 2, 173 CFU/ml vs. 473 CFU/ml.
Coagulase negative staphylococcus ssp. were the most frequently isolated
microorganisms and was found in 91% of human milk samples and 100% of bovine
milk samples. Staphylococcus aureus were identified in one human milk sample from
a mother in the PG subgroup and in one bovine sample from a cow suffering from
untreated mastitis as well as both pooled bovine vat samples. Streptococcus ssp. and
yeast were only found in bovine samples.
The TG subgroup had the highest Na+ concentration of the human milk samples (8.04
± 2.40 mM), significantly highly than the control group (4.32 ± 1.18 mM; p<0.001).
There was no significant difference in Na+ concentration between the TG and PG
subgroups. The Na+/K+ ratio was significantly higher in the TG subgroup (0.55 ±
0.14) compared to the control group (0.34 ±0.09) (p<0.001); there was no significant
xviii

difference in ratio between the PG and TG subgroups (p=0.10). No sample recorded a
Na+/K+ ratio above 1, consistent with the physiological observations and indicative of
no mother presenting with mastitis.
Untargeted metabolomic analysis found compositional differences between the
human control and nipple pain groups, in particular samples from the TG subgroup.
Compositional variations between milk from the control and nipple pain subgroups
was identified using principal component analysis and PC4 best represented the
differences in metabolite composition between the groups. This result is consistent
with the subtlety of the nipple pain condition. A list of the most influential
metabolites based on their correlation loadings (explained within 50-100% of the
model) was determined. The most influential metabolites with respect to the TG milk
samples were included isoleucine, proline, galactose and some as yet unidentified
metabolites.
Conclusion
As nipple pain is often a precursor to mastitis the results from this study will form a
basis for further development using metabolomics as a tool for more efficient
detection and treatment of breast infection and inflammation within the nipple and
breast.
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1 Literature Review
1.1
1.1.1

Introduction
Benefits of breastfeeding for mother and infant

Human milk is considered the ‘gold standard’ nutrition for infants as it provides
optimal nutrition, promotes normal growth and development and reduces the risk of
developing illness or disease (Heikkila & Saris, 2003). The WHO (2003)
recommends exclusive breastfeeding for the first six months of age, with
complementary breastfeeding up to two years and beyond. In Australia the National
Health and Medical Research Council (NHMRC) Guidelines recommend exclusive
breastfeeding for the first six months of age and the continuation of breastfeeding for
up to at least one year (NHMRC, 2012). Where breastfeeding is not possible human
donor milk is the preferred substitution ahead of infant formula (Hartmann, Pang,
Keil, Hartmann & Simmer, 2007).

Breast milk is readily available, financially affordable and an environmentally
sustainable source of sustenance for developing infants and contributes to numerous
positive health outcomes for both the mother and infant. An American based study by
Bartick and Reinhold (2010) found that if 90% of US families could comply with the
medical recommendation to breastfeed exclusively for 6 months that the United States
would save almost $13 billion a year and prevent an excess of 911 deaths annually,
nearly all of whom would be infants (95%) (Table 1.1).
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Table 1.1

Excess costs and deaths at current breastfeeding rates compared
with projected costs if 90% or 80% of US parents complied with
the medical recommendation to exclusively breastfeed for 6
months.
Excess Costs Compared

Excess Costs Compared

with 90% Compliance

with 80% Compliance

(Excess Deaths), 2007

(Excess Deaths), 2007

$US

$US

Total

12 974 676 651 (911)

10 491 841 489 (741)

SIDS

4 725 328 464 (447)

3 722 074 013 (352)

NEC deaths

2 631 165 267 (249)

2 218 109 495 (210)

LRTI deaths

1 820 102 146 (172)

1 537 915 767 (146)

Otitis media

908 793 396

765 766 295

Atopic dermatitis

601 358 918

497 497 274

Childhood Obesity

592 100 121

404 195 504

LTRI hospitalisation

451 592 572

381 578 219

Childhood asthma

335 796 234

229 194 255

NEC

266 536 884

219 843 084

216 869 872 (21)

148 022 294 (14)

186 016 678

162 076 307

133 422 239 (13)

133 422 239 (13)

95 231 472 (9)

64 999 258 (6)

T1D

8 376 168

5 717 067

Childhood leukaemia

1 986 220

1 430 416

Childhood asthma deaths
Gastroenteritis
Childhood leukaemia deaths
Childhood T1D deaths

This table was reproduced from Bartick & Reinhold (2010)
LRTI- Lower respiratory track infection
NEC- Necrotizing enterocolitis
T1D- Type 1 diabetes
Breastfeeding has been linked to many immediate and lifelong benefits for the
developing infant. Research has shown that an exclusively breastfed infant between
the ages of 1-6 months consumes an average of 750-800ml over a 24 hour period
(range 500-100 ml) (ABS, 2015). A study of nine year old children by McCrory and
Layte (2012) found that children who were breastfed (>13 weeks) had a 38% reduced
2

risk of obesity and those who were breastfed for 26 weeks and beyond had a 51% risk
reduction for obesity. Additional studies have found a dose-response effect on
cognitive and neural development, where the duration of breastfeeding correlated
positively with an increase in IQ (Michaelsen, Lauritzen, Mortensen & Jorgensen,
2003).

Functional nutrients such as human milk oligosaccharide (HMO) in human milk
provide the microenvironment for gut protection and maturation (Newburg, 2005).
Due to the immature nature of the infants gut at birth they are more susceptible to
intestinal and systemic infections. The ingestion of breast milk, in particular
colostrum, results in differentiation of immature to mature epithelia (with subclasses
of enterocytes and lymphoid tissue) and active maturation of the infants own mucosal
immune system for protection against infection and immune mediated disease
(Walker, 2010).

Furthermore, research has found that breastfed infants are less susceptible to a range
of serious illnesses and conditions such gastroenteritis, respiratory illness and otitis
media (AIHW, 2009). Conversely, exclusive formula feeding presents numerous
health risks to the developing infant including increased risk of allergies including
eczema and atopic dermatitis, and (potential) ingestion of contaminants (Tait, 2000).

Breastfeeding has been found to provide many maternal benefits and research
suggests a dose-response effect with breastfeeding and health risk (Godfrey &
Lawrence, 2010). A history of lactation has been associated with a reduced risk of
cancer including breast and ovarian and decreased incidence of type II diabetes (Ip,
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Chung, Ramam, Trikalinos & Lau, 2009). The practice of breastfeeding enhances the
mother-child bond and therefore positively correlated with a decrease in post-partum
depression and associated with a decreased rate of neglect and abuse (Strathearn,
Mamun, Najman & O'Callaghan 2009).

Numerous maternal benefits are associated with breastfeeding such as a decrease in
maternal post-partum blood loss, more rapid involution of the uterus and a quicker
return to pre-pregnancy body weight than mothers who don’t breastfeed (American
Academy of Pediatrics, 2012). In mothers with no history of gestational diabetes
breastfeeding duration was found to decrease the risk of developing type II diabetes
by 4-12% (Schwarz et al., 2010). Furthermore mothers who breastfeed are less likely
to develop rheumatoid arthritis (Karlson, Mandl, Hankinson, & Grodstein, 2004),
hypertension, hyperlipidaemia and cardiovascular disease including coronary heart
disease (Godfrey & Lawrence, 2010).

Given the multitude of short and long term benefits of breastfeeding to the mother and
infant, promotion of breastfeeding is of global importance given the increase in
incidences of the diseases aforementioned, particularly in developing countries where
breastfeeding rates have been falling.

1.1.2

Breastfeeding incidence and duration in Australia

In Australia and internationally breastfeeding has received increased attention as a
means for improving public health, contributing to health, nutrition and wellbeing of
infants and mothers. Benefits of breastfeeding are largely dose-dependent, therefore
extending duration is highly desirable in terms of facilitating infant growth and
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development and ensuring maximal maternal benefit. A national survey in 2001 found
87 % of infants aged up to three years of age had obtained nutrition from breast milk
at some stage, in the form of exclusive breastfeeding or complementary breastfeeding
with the addition of solids or substitutes (ABS, 2003). The incidence of breastfeeding
post hospital discharge has increased from 40-45% in the 1970’s to 82% and 83% in
1995 and 2001 respectively (ABS, 2003). Despite rising rates in initiation of
breastfeeding, duration rates still dramatically decline despite recommended duration
of one year by the NHRMC (2010) or up to two years by the WHO (2001).

Rates of duration of breastfeeding between 1995 and 2001 showed that 48% of
mothers were still breastfeeding at 6 months, however this decreased to 23% at 1 year
and only 1% of mothers were still breastfeeding 2 years after parturition (Figure 1.1)
(NHRMC, 2003).

Figure 1.1
Prevalence of breastfeeding in Australia in 2001.
Reproduced from The National Health and Medical Research Council (2003).
More recent research suggests that the incidence and duration of breastfeeding in
Perth, Western Australia, has increased significantly, in particular between 1992/35

2002/3 where prevalence reached national targets for breastfeeding (>90% of mothers
were breastfeeding at the time of discharge) (Graham, Scott, Binns & Oddy, 2005). In
Perth 93% of mothers were breastfeeding at discharge from the hospital between
2002-2004 (Win, Binns, Zhao, Scott and Oddy, 2006). Additionally, the 2010
Australian National Infant Feeding Survey (NHMRC, 2010) found breastfeeding
initiation rates have increase to 90-96% on discharge from hospital, with 50-60% and
22-28% still breastfeeding at 6 and 12 months respectively. Despite these initiation
rates being higher than the national average in 2001, previously mentioned as 83%,
and approaching those reported for Nordic countries (Lande et al., 2003; Ekstroem,
Widstroem & Nissen, 2003), the increase in initiation doesn’t appear to be
accompanied with an increase in breastfeeding duration (Scott, Binns, Oddy&
Graham, 2006). Breastfeeding rates dropped to 45.9 % (of whom 12 % were
exclusively breastfeeding) by 6 months post partum and by one year only 19.2 %
were reported to be breastfeeding (Scott et al., 2006).

Whilst hospital policy, promotion and support have increased breastfeeding initiation
rates, breastfeeding duration has not substantially improved. This is likely due to the
need to return to work and difficulties experienced by breastfeeding women such as
perceived inadequate milk supply, nipple pain and mastitis which lead to premature
weaning (Abou-Dakn, Richardt, Schaefer-Graf & Wockel, 2010).

1.2

Anatomy of the lactating breast

An understanding of the macroscopic and microscopic anatomy of the lactating breast
can help us better understand the development of pathologies and their observed
effects on the mammary tissue and its’ secretions. Breast pathologies, for example
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mastitis, can compromise the integrity of the breast, therefore changes in milk
composition are considered to be an important indicator of the physiological state of
the mammary tissue (McManaman & Neville, 2003). A fundamental knowledge of
the anatomy of the breast can aid in diagnosis and treatment development.

1.2.1

Macroscopic anatomy

The human breast is comprised of two main tissues, adipose and glandular (secretory),
held loosely together by a network of fibrous connective tissue called coopers
ligaments (Ramsay, Kent, Hartmann, R. & Hartmann, P., 2005) (Figure 1.2). It is
important to note that there is large variation between women. Not only do the breasts
of some women contain more adipose tissue, the amount of adipose tissue situated
between glandular tissue is also highly variable (Geddes, 2007). In some cases the
amount of glandular tissue was found to exceed adipose tissue by double (Geddes,
2007). A study by Ramsay et al. (2005) found no correlation with milk production or
storage capacity and the estimated volume of secretory or glandular tissue (including
the number of ducts and the mean diameter of the milk ducts) (Ramsay, et al. 2005).

The glandular tissue contains a secretory system, which is drained by a ductal system
that stores and transports milk to the nipple during lactation. Based on the 1840’s
Cooper’s dissections of the lactating breast (Cooper, 1840), it was previously believed
that the lactating breast contained 15-20 ducts (however, Cooper identified up to 22
ducts in one instance), with 7-12 generally found to be patent. However, more recent
studies using 2D ultrasound (Ramsay et al. 2005) found the glandular tissue of each
breast to contain approximately 9 milk ducts (range 4-18) with a mean diameter of 2 ±
0.8 mm (range 1.0-4.4 mm) (Ramsay et al. 2005). Another study by Love and Barsky
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(2004), using a combination of in vivo and in vitro techniques, resolved that 90 % of
nipples contained 5–9 milk ducts (with a nipple orifice), arranged in a central and
peripheral orientation.

Furthermore Cooper (1840) described the proximal ducts to be large sac like
structures that converged into one main milk duct, known as a lactiferous sinus.
However, recent studies using 2D ultrasound imaging (Ramsay al. 2005) and 3D
ultrasound imaging (Gooding, Finlay, Shipley, Duck & Halliwell, 2010) found an
absence of lactiferous sinuses and rather the main milk ducts to be relatively small
with expanding areas coinciding with merging ducts. Furthermore the ducts have been
found to dilate during milk ejection in order to transport milk towards the nipple for
the suckling infant (Ramsay et al. 2005).

Figure 1.2
Macroscopic anatomy of the normal lactating mammary gland.
Reproduced from Ramsay et al. (2005).
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1.2.2

Microscopic anatomy

The mammary gland is comprised of lactocytes, ductal epithelial cells, myoepithelial
cells and mammary stem cells (Berry, 2009). The lactocytes, secretory epithelial cells,
line the alveoli of the breast and are responsible for producing and secreting milk into
the luminal space of the alveoli (Berry, 2009). Lactocytes are cuboidal/columnar in
shape and link with several specialised junctions, for example tight junctions, which
prevent the passage of substances external to the alveolus during established lactation
(Linzell & Peaker, 1971). The alveoli are surrounded by myoepithelial cells and a
vascular connective tissue stroma that contains adipocytes and fibroblasts
(McManaman & Neville, 2003). Myoepithelial cells function during milk ejection
when suckling stimulus causes the release of oxytocin into the maternal circulation.
Oxytocin binds to myoepithelial cells and causes them to contract (neuroendocrine
reflex) thereby ejecting milk from the alveoli into the ducts towards the nipple to be
removed by the infant or a breast pump (McManaman & Neville, 2003).

The cytoplasm of lactating alveolar cells is dense in mitochondria and there is an
extensive rough endoplasmic reticulum network, as would be expected in a highly
active secretory cell (McManaman & Neville, 2003). Additionally the cells contain a
Golgi apparatus and secretory vesicles containing casein micelles located in the apical
region of the cell (McManaman & Neville, 2003). The alveolar epithelial cells are
connected through an apical junctional complex and the epithelial cells on the basal
side of the alveolar contact the myoepithelial cells and basement membrane. This
forms a separation between the epithelial cells and the stroma and vascular system,
creating a barrier for the transfer of substances from blood or stromal cells to the milk.
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1.3

Physiology of lactation

The prepubescent breast consists of a basic network of immature ducts, formed by
epithelial cells, submerged in the mammary fat pad (Thomas, Williams and
Hartmann, 2010). At puberty an increase in ovarian hormones stimulates the ducts to
branch out and extend from the nipple and pervade the surrounding fat pad creating a
complex ductal network (Thomas et al., 2010). However, the human breast does not
reach maximal growth and functional development until pregnancy and parturition
(Hale & Hartmann, 2007). The ability to secrete milk develops during pregnancy and
is regulated by changes in multiple hormones.

Lactation is defined as the stage of sustained milk production (Pang & Hartmann,
2007). The initiation of lactation occurs in two stages, secretory differentiation and
secretory activation (Pang & Hartmann, 2007). Secretory differentiation describes the
stage of pregnancy where buds on the end of each duct proliferate and then
differentiate to form alveoli lined with functional lactocytes capable of milk synthesis
(Hale and Hartmann, 2007). Secretory activation describes the onset of copious milk
secretion in association with changes in milk composition as a result of progesterone
decline and increase in prolactin secretion at parturition (Pang & Hartmann, 2007). It
is essential that secretory activation closely precede parturition to ensure the newborn
has a continuous source of nourishment.

1.3.1

Secretory differentiation

Secretory differentiation usually occurs in the later stages of pregnancy at around 24
weeks gestation and is characterised by rapid growth of both the ductal and alveolar
structures accompanied by accumulation of the first secretion (colostrum) within the
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alveoli and ducts (Hassiotou & Geddes, 2013). Secretory mammary epithelial cells
differentiate into lactocytes, functional mammary epithelial cells, with the ability to
synthesize unique milk metabolites such as lactose, casein, alpha-lactalbumin and
fatty acids (Pang & Hartmann, 2007). Milk synthesis describes the anabolic process
leading to the accumulation of milk components in the lactocytes (Pang & Hartmann,
2007).

Alveolar development occurs during the early stages of pregnancy and can be
described as the proliferative activity that leads to the development of the mature milk
secreting unit (Pang & Hartmann, 2007). Reproductive hormones; oestrogen,
progesterone and prolactin together with metabolic hormone’s growth hormone,
glucocorticoids and insulin must be present for secretory differentiation to occur
(Pang & Hartmann, 2007).

1.3.2

Secretory activation

Secretory activation occurs shortly after parturition in women, and it is defined as the
onset of copious milk production and marks the commencement of milk secretion
(Jensen, 1995). Clinical signs of secretory activation are an abrupt sensation of breast
engorgement occurring between 24-72 hours post parturition (Arthur, Smith &
Hartmann, 1989). Progesterone withdrawal at parturition, due to the expulsion of the
placenta, initiates secretory activation, however the hormones prolactin, insulin and
cortisol must also be present (Pang & Hartmann, 2007). Blood prolactin levels are
high during early lactation, shown to stimulate milk synthesis and proliferation
(Neville et al., 2002). This results in accumulation of milk in the alveoli followed by
copious milk secretion.
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Post parturition the basement membrane (separating the mammary stroma from the
epithelium) experiences a change in integrity characterised by tightening and reduced
permeability, resulting in the control of systemic and stromal signalling to the
mammary epithelium (Hassiotou & Geddes, 2013). This serves to control the
movement of milk components or their precursors via paracellular pathways between
the systemic circulation lactocytes and alveolar lumen or the lactocytes (Hassiotou &
Geddes, 2013).

1.4

Secretory pathways

Secretory alveoli are enclosed by a basement membrane separating them from the
surrounding stroma (Thomas et al., 2010). The basement membrane is important in
regulating the activity of the alveolar cells and the components that can pass from the
mother’s bloodstream or interstitial fluid into the milk (Thomas et al., 2010). There
are a number of potential barriers that control the transfer of exogenous substances
from the blood or stromal cells to the milk. Metabolites both endogenous and
exogenous to the mother can enter the milk via means of transcellular and paracellular
pathways.

1.4.1

Transcellular pathways

The transcellular pathway allows movement across the lactocytes and is the mode of
movement employed by fat globules, ions (e.g. calcium), glucose, protein hormones,
immunoglobulins, and water (Pang and Hartmann 2007).

The transcellular pathway can be divided into four general mechanisms of movement.
Two exist for the secretion of endogenously generated molecules, aqueous solutes
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including proteins and oligosaccharides and nutrients such as lactose, citrate,
phosphate and calcium, and two exist for the transport of exogenous molecules,
including numerous macromolecules derived from serum and stromal cells and many
ions and small metabolites (McManaman & Neville, 2003).

1.4.2

Paracellular pathway

The paracellular pathway allows direct, bi-directional and extracellular movement of
low molecular weight substances and macromolecular solutes from the serum or
interstitial space into the milk (McManaman & Neville, 2003). The paracellular
pathway becomes closed during lactation as a result of tight junctions between
epithelial cells, at which point transcellular pathways act as the only route for transfer
of solutes to milk (McManaman & Neville, 2003). The transport of metabolites
through this pathway is largely affected by the functional capacity of the mammary
gland and can be a direct indication of the physiological state of the lactating breast.
Inflammation resulting from mastitis can cause the paracellular pathway to reopen,
allowing small molecules including sodium, chloride and glucose to pass freely into
the milk space, while molecules such as lactose, potassium and calcium pass from the
milk space into the plasma (Jensen, 1995).

1.5 Pathology of the human breast
Breastfeeding is the preferred source of nutrition for all newborns however it is not
always an option for all women, as some women experience physiological,
psychological or clinical difficulties that prevent them breastfeeding either
temporarily or for an extend period of time. A West Australian study of 306
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breastfeeding women by Fetherston (1997) found that mastitis is the third most
common reason for weaning, with one in four women citing mastitis as their reason
for ceasing breastfeeding (Michie, Lockie & Lynn, 2003). More recently a study by
Abou-Dakn et al. (2010) found that the most common reason for premature cessation
of breastfeeding in early lactation, affecting up to 50% of mothers, is nipple pain and
mastitis. In weeks 1-3 insufficient milk supply (37.3%), commonly due to mastitis
(Abou-Dakn et al., 2010), followed by breast pain or mastitis (32.9%) was the most
common reasons for cessation of breastfeeding (Schwatrz, 2002). Women who
reported pain in the first three weeks of breastfeeding were more likely to cease
breastfeeding than mothers who reported pain beyond three weeks (Schwartz et al.,
2002).

The study by Schwartz et al. (2002) also found that women who developed mastitis in
the first three weeks post partum were nearly six times more likely to cease
breastfeeding than women not suffering from mastitis. Furthermore with every day of
pain in the first three weeks there was an increased risk of 10-25% for termination of
breastfeeding (Schwartz et al. 2002). Thus mastitis, pain and days with pain in the
first three weeks post partum are important clinical factors associated with
breastfeeding termination in mothers who prenatally identified themselves as mothers
who intended to breastfeed (Schwartz et al., 2002).

Mastitis or, inflammation of the mammary tissue, is a debilitating disease that largely
contributes significantly to weaning in the first three weeks post partum. Factors
associated with mastitis include pain and discomfort when breastfeeding, ineffective
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milk removal, reduced milk flow and the inability to provide sufficient nutrition for
the growing infant (Foxman, D’Arcy, Gillespsie, Bobo & Schwartz, 2002).

1.5.1

Nipple pain

Nipple pain, with or without trauma, is a complication associated with breastfeeding
found to have a significant impact on breastfeeding in the first few weeks post
partum. The incidence is reported to range from 34% up to 96%, with the highest
prevalence on day 3 and decreasing by day 7 (Page, Lockwood & Guest, 2009).
Incorrect positioning and attachment has been implicated as the major cause of nipple
pain, with speculation that increases in suction pressure applied by the infant may be a
cause of pain in some women (McClellan et al., 2008); vasospasm, tongue tie and
eczema are less common causes of nipple pain. Nipple infection accounts for a
proportion of the cases of nipple pain and is thought to be a consequence of nipple
trauma. Determining the cause of nipple pain is often difficult, for example severe
pain combined with whitish changes of the nipple is often misdiagnosed as Candida
spp., resulting in many breastfeeding women receiving incorrect treatment (Holmen &
Bache, 2009). The involvement of bacteria in nipple pain is still largely unknown,
however a study by Eglash, Plane & Mundt (2006) stated that women with nipple
pain without symptoms of acute mastitis were 3 times more likely to culture
pathogenic bacteria, most commonly Staphylococcus aureus, than candidiasis.

Most lactation consultants agree that nipple soreness in the first week post partum is
quite normal, however nipple pain that exceeds the first week is normally a sign of a
greater problem that requires skilled assessment and observation (Tait, 2000).
Associated with both frictional and suction lesions, pain can range from an
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uncomfortable feeling to severe pain possibly preventing the continuation of
breastfeeding (Page et al., 2009). As a result, as many as one third of mothers who
experience these complications may change to alternate methods of infant nutrition in
the first six weeks after birth (Page et al., 2009).
1.5.2

Mastitis

Mastitis and breast abscess occurs in all populations and at any stage of lactation.
WHO (2000) reported the incidence of mastitis to affect ~20% of all lactating women,
with 74-95% of cases occurring in early lactation (first 12 weeks after birth). Mastitis
can be defined as cellulitis of the interlobular connective tissue within the mammary
gland of the breast (Foxman et al., 2002). Clinical symptoms range from focal
inflammation with minimal systemic symptoms to abscess and septicaemia in more
severe cases (Foxman et al., 2002). Systemic symptoms such as pyrexia and flu like
symptoms are often sudden in their onset and vary in severity, with women reporting
duration of symptoms ranging from one to 12 days (Fetherston, 2001). The affected
breast may appear red, hot and swollen. Factors associated with mastitis also include
pain, discomfort when breast feeding and poor drainage (reduced milk removal)
which may cause some women to cease breastfeeding (Foxman et al., 2002).

Past research has determined that mastitis is most frequently the result of stasis of
milk, without significant deviation in ‘normal/healthy’ bacterial counts and species.
On occasions where milk stasis is not the cause of mastitis, milk infection is often the
cause of bacterial colonisation of the breast and can be detected through increased
colony counts and predominance of a small number of bacterial clones (Michie et al.,
2003). Consequently, mastitis is frequently defined as infectious or non-infectious.
The most common type of mastitis is non-infectious mastitis, where inflammation of
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the breast tissue results from milk stasis, blocked ducts, engorgement or physical
injury (Crepinsek, Crowe, Michener & Smart, 2012).

Infectious mastitis may result from trauma to the skin of the nipple, damaging the
integrity of the breast and consequently providing a route for microbial infection
(Crepinsek et al., 2012). The most common portal of entry for bacterial infection in
women with mastitis is assumed to be through nipple pores into lactiferous ducts
(Fetherston, 2001). Infectious mastitis is most often associated with Staphylococcus
aureus, an organism that can cause an abscess to develop if left untreated (Amir,
Forster, McLachlan & Lumley, 2004). A study by Delgado et al. (2009) found that
Staphylococcus epidermidis was the most prevalent staphylococcus species isolated
from mastitic milk and was prevalent in concentrations significantly higher than that
normally present in the healthy mother. S. epidermidis has been increasingly
recognised as an opportunistic pathogen and as a casual pathogen of mastitis, despite
being a normal inhabitant of healthy human skin and mucosal microflora (Delgado et
al., 2009). Staphylococci are known for their pronounced genetic variability and S.
epidermidis has been found to have mechanisms for adhesion and biofilm formation.
Its resistance to certain antibiotics has increased in recent years and it is consequently
emerging as a common nosocomial pathogen (Ziebuhr et al., 2006).

Alternatively mastitis can be viewed as a continuum of a disease where the initial
non-infectious mastitis develops into a secondary infectious mastitis resulting in the
formation of an abscess (Crepinsek et al., 2012). Hence infection, when it occurs, is
not primary, but the result of stagnant milk providing a medium for bacterial growth.
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Although effective milk removal through feeding, pumping or both is the foundation
for all treatment to remove stagnant milk, antibiotics are usually prescribed
prophylactically to cover possible bacterial infection (Jahanfar, Ng & Tang, 2013).
However, antibiotic prescription is not based on analysis of breast milk, therefore it is
not known how many cases are unnecessarily adding to the increase in antibiotic
resistant strains of bacteria. To reduce the number of bacteria becoming resistant to
antibiotics it is important to correctly diagnose each case of mastitis to reduce their
inappropriate use. Thomsen, Hansen & Moller (1983) proposed that levels greater
than 103 CFU/ml of pathogenic bacteria in breast milk was an indication that
antibiotic treatment is required. They concluded that a high bacterial count together
with leukocytosis was indicative of infection. Note that the colony forming unit
(CFU) count does not take into account the normal bacterial content in milk.

1.5.3

Breast thrush

Some breastfeeding mothers also experience a burning pain in the nipple/breast
known as breast thrush, which occurs in 10% of women. Although the exact cause of
breast thrush has not yet been confirmed, many researchers believe it is the result of
Candida albicans infection (Amir et al., 2011). However, due to the presence of other
microorganisms it is difficult to identify C. albicans as the sole cause. Consequently,
it is possible that breast thrush is the result of co-infection caused by the presence of
multiple microorganisms such as S. aureus or E. coli as well as C. albicans or other
Candida spp.
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Australian milk banks currently examine the bacteriology of donor milk by culturing
all donations on cysteine-lactose-electrolyte deficient (CLED) agar and 5% horse
blood agar and quantifying colony growth (Hartmann et al., 2007). Critical limits
have been defined for the level of contamination acceptable in raw milk and donations
containing a confluent growth of microorganisms exceeding 105 CFU/ml are
discarded (Hartmann et al., 2007). However, this is not routine practice for the
diagnosis of mastitis or causative agents of nipple pain, nor is it conducted before the
administration of antibiotics or alternative medications.
1.6

Composition of human milk

Milk is a complex biological matrix made up of thousands of compounds. The
complexity of milk reflects the activities of the mammary secretion and transport
processes, the physiological condition of the breast and the unique nutritional
requirements of the developing newborn (McManaman & Neville, 2003). The
constituents in milk provide nutrition, structural components for cellular membranes
and non-nutritive functional components e.g. immunological factors (Jensen, 1995).

The composition of human milk is dynamic and highly variable. Variation occurs
over the course of lactation, between and within feeds, diurnally, between mothers
and with treatment of expressed milk including storage and pasteurisation (Chung,
2014). The mother’s nutrition, body mass index (BMI) and parity have also been
found to influence milk composition (Hsu et al., 2014). A study by Eilers et al. (2011)
found a positive correlation with milk leptin concentration and BMI, suggesting that
mothers' adiposity may increase the leptin levels in milk.
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Milk composition changes over the course of lactation, which can be divided into the
known milk stages colostrum, transitional milk and mature milk. Colostrum marks the
first phase of lactation spanning the first 3-5 days after parturition. Colostrum has a
distinct biochemical and cellular composition, characterised by high concentrations of
protein, fat-soluble vitamins, minerals, and immunoglobulin, designed to provide
enhanced immunological protection and nutritional and developmental support to the
infant (Hassiotou & Geddes, 2013).

Transitional milk proceeds the colostrum stage lasting up until 2-3 weeks postpartum
and has higher levels of fat, lactose and water soluble vitamins and contains more
calories than colostrum (Jensen, 1995) (Table 1.2). Thereafter, breast milk is said to
have reached the mature phase, the final stage of milk transition, which is maintained
for the remainder of lactation (Hassiotou & Geddes, 2013). Mature milk is comprised
of 90% water and 10 % carbohydrates, proteins and fats.

Table 1. 2

Human milk composition between 1 and 28 days post partum.
Days post partum

Component

1

2

3

4

5

14

28

Yield g/24 hr

50

190

400

625

700

1100

1250

Lactose (g/L)

20

25

31

32

33

35

35

Fat (g/L)

12

15

20

25

24

23

29

Protein (g/L)

32

17

12

11

11

8

9

Recreated from Jensen (1995). Handbook of Milk Composition.
The volume of milk, lactose and fat increase and protein decreases as lactation
progresses days post partum.
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1.6.1

Macronutrients and micronutrients

Milk is a highly complex suspension of lipids, proteins, carbohydrates, secretory
immunoglobulins, calcium and various other macro and micro molecules, ions and
bioactive factors (Thomas et al., 2010). Table 1.3 is a summary of macronutrient
composition of human milk findings from past studies. Fat content (grams per 100ml)
can be identified as the most variable nutrient across populations, however individuals
within a population showed equal if not greater variations (Prentice, 1995; Wojcik,
Rechtman, Lee, Montoya & Medo, 2009).

Table 1.3

Summary of macronutrient composition from past studies.

Population

Fat

Lactose

Protein

Reference

Philippines (Manila)

3.93

7.31

0.85

WHO, 1985

The Gambia

3.78

7.74

1.09

Prentice et al., 1981a

Australia

3.74

6.14

0.92

Mitoulas et al., 2002

Bangladesh

2.66

8.08

1.00

Brown et al., 1986

Sweden

5.69

6.70

0.83

WHO, 1985

Guatemala

2.40

8.00

0.94

WHO, 1985

Zaire

3.30

6.30

1.30

WHO, 1985

USA (DARLING)

3.80

7.40

1.10

Nommsen et al., 1991

Mean

3.66

7.21

1.00

Reproduced from ‘Predictors of breast milk macronutrient composition in Filipino
mothers’, Quinn, Largado, Power & Kuzawa (2012).
Contents recorded in grams per 100ml and calculated where necessary using a
nitrogen to protein conversion factor of 6.38.
The summary of milk macronutrients from past studies found that fat content of
human milk varied between 2.4 to 5.69 g/100ml across populations, however women
within the same population showed equal if not greater variation than different
populations. Carbohydrate and protein content of milk showed less variance, with
carbohydrate ranging from 6.14 to 8.08 g/100ml and protein ranged from 0.83 to
1.03 g/100ml.
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During the initiation of secretory activation the paracellular pathway closes,
preventing movement of small molecules from serum or interstitial space into the
milk and vice versa. The closure of tight junctions blocks the paracellular pathway
preventing lactose (made by the epithelial cells) from passing from the alveolus to the
plasma and sodium and chloride from entering the alveolar lumen from the interstitial
space (McManaman & Neville, 2003). This resulted in a fall in sodium and chloride
concentration and an increase in lactose concentrations in milk (Table 1.4), which
occurs immediately after birth and is complete by 72 hours post delivery
(McManaman & Neville, 2003).
Table 1.4

Changes in selected milk components in early lactation.
Hours post partum

Component (mmol/L)

21

48

60

96

120

-

180

350

560

540

Lactose

100

140

160

160

160

Potassium

13.8

15

18

18

18

Sodium

34

25

16

14

14

Chloride

44

35

25

20

20

Calcium

4.0

6.0

6.6

7.6

8

Volume (ml/day)

Recreated from Jensen (1995). Handbook of Milk Composition.
The volume of milk and amount of lactose, potassium and calcium increase and
sodium and chloride decrease as lactation progresses hours post partum.
Epithelial cells are connected via an apical junctional complex composed of adherens
and tight junctional elements that act to prevent direct paracellular exchange of
interstitial and milk components (McManaman & Neville, 2003). However, during an
episode of mastitis or inflammation the tight epithelial junctions dividing milk and
plasma become compromised and the paracellular route reopens, causing plasma
components such as sodium and chloride to leak into the milk (McManaman &
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Neville, 2003) and components such as lactose and potassium to pass from the milk
into the plasma (Jensen, 1995). An elevated milk sodium concentration above the
norm (5-6mmol/L) has previously been considered indicative of infection. However,
as milk composition varies largely between individuals, it is difficult to determine if
sodium concentration levels are an accurate measure of infection or inflammation and
consequent damage to the mammary tissue. For this reason, the sodium to potassium
ratio has recently been suggested as a possible indication of infection or inflammation
as it accounts for individual differences, with a elevated sodium to potassium ratio
above 1.0 being considered indicative of mastitis (Aryeetey, Marquis, Timms, Lartey
& Brakohipa, 2008).

1.7 New methods of milk analysis
There have been many studies in recent years on bovine mastitis, described as a
production disease, as it is the most expensive disease effecting dairy farms world
wide, causing enormous financial loss to the dairy industry (Hogeveen, Huijps &
Lam, 2011). Metabolomics has been utilized increasingly within the food industry and
has been proposed as a useful tool in the dairy industry to ensure proper milk
composition and milk of the highest quality (Boudonck, Mitchell, Wulff & Ryals,
2009). Previously diagnosis of mastitis in domesticated animals focused
predominantly on quantitative measures, most commonly monitoring milk somatic
cell count, which is known to increase during an episode of mastitis (Michie et al.,
2003). Estimates of the milk cell count are widely employed to assess milk quality,
with lower cell counts attracting higher prices. More recently, a study by Sundekilde
et al. (2013) found a series of metabolite biomarkers, including isoleucine, lactate,
butyrate and acetate, that were associated with elevated somatic cell count in bovine
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milk and suggested that detection of these could be a potential tool to determine milk
quality, diagnose mastitis and consequently determine whether milk should be
discarded. This knowledge and technology could also be applied to human milk,
determining metabolome changes as a means for diagnosis of breast complications
particularly mastitis. Furthermore, it can be reasoned that if bacterial and fungal
infections are a causative agents of nipple trauma and mastitis, their presence and
associated endogenous metabolites will contribute to the composition of expressed
milk. Consequently, if severity of trauma is correlated to underlying infection, then
profiling the metabolome of expressed milk may identify differences in metabolite
composition between mothers experiencing varying degrees of pain and discomfort.

1.7.1

Metabolomics

Metabolomics revolves around the central concept that an individual’s metabolic state
is a close representation of their current physiological state indicating their health or
disease status (Fanos, Barberini, Antonucci & Atzori, 2012). Our metabolome is not
solely determined by our genes but also influenced by our environment and unique
body flora and therefore consists of a mix of endogenous and exogenous metabolites,
some of which may include food component or environmental chemicals.
Metabolomics aims to improve understanding of physiology and metabolism by using
analytical chemistry techniques to assess metabolic changes in biofluids, tissues and
cell extracts to create a metabolic profile (Veselkov et al., 2011).

Metabolomics aims at a quantitative analysis of a large number of low molecular
weight metabolites existing as substrates or products in metabolic pathways present in
all living systems (Moco, Collino, Rezzi & Martin, 2013). The metabolomics
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approach is based on highly sensitive analytical methods with data obtained by
quantifying multiple metabolites or small molecules in test samples (Fanos et al.,
2012). A typical metabolomic data matrix consists of metabolites and their relative
abundances for a sample set including two or more conditions (control and study
group/s). The direction of statistical analysis is to identify differences in presence and
abundance of metabolites between control and study groups (De Livera et a., 2012).
Current techniques commonly used in metabolomic analysis include mass
spectrometry coupled with gas chromatography (GC-MS) or liquid chromatography
(LC-MS) and nuclear magnetic resonance (NMR) (Fanos et al., 2012).

1.7.2

Gas chromatography mass spectrometry (GC-MS)

GC-MS is a synergistic combination of two techniques, firstly gas chromatography
which separates the components of a mixture of molecules and the second, the mass
spectrometer which provides structural information of each component measured
(Kitson, Larsen & McEwen, 1996). In GC-MS-based metabolomics, complex
mixtures of metabolites from a cell, tissue or biofluid are analysed.

Gas chromatography involves volatilization of the sample in a heated inlet, separation
of the components of the mixture in a capillary column and detection of each
component at the detector (Figure 1.3). A carrier gas (mobile phase) is used to transfer
the volatilised sample from injector through the column where separation of each
analyte is determined by the partition of each component between the mobile and
stationary phase. Only materials that can be volatilised without decomposition are
suitable for analysis by gas chromatography.
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Within the mass spectrometer analytes are ionised and measured as a function of their
mass to charge ratio and represented as a mass spectrum of ions each in relative
abundance, which provides a quantitative measure of the abundance of each ionic
species as it elutes from the column (Hubschamann, 2008). The measurements are
calibrated against ions of known mass to charge ratio and compared to a database of
known metabolites to determine presence and abundance of metabolites in a sample
(Hubschamann, 2008).

Figure 1.3
A simplified model of a gas chromatograph mass spectrometer.
Reproduced from Dunnivant and Ginsbach, 2008.
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Interrogation of the GC-MS data requires deconvolution of the chromatogram to
distinguish metabolites from non-biological analytes (e.g. artefacts from storage
conditions) and to identify these from instrument noise and co-eluting analytes. GC
retention times and calculated retention indices together with reproducible and
predictable mass fragmentation (for comparison of the features with analysed
metabolite standards) are used to identify metabolites by composition, against a
library of metabolite mass spectra (Gummer et al., 2012). When used for
metabolomics studies, the use of appropriate quality control measures, including
internal standards to account for sample extraction and instrumental inter-sample
efficiencies and system equilibration, is imperative (Gummer et al., 2012).

1.7.3

Untargeted metabolomics

Metabolomics is a reflection of genetic factors with the expressed metabolites defined
as the end point. Mapping a person’s metabolome against their phenotype has been
proposed as a useful tool for clinical systems biology to detect metabolic changes
even before disease symptoms appear (Smolinska, Blanchet, Buydens & Wijmenga,
2012). Blood and urine samples are frequently used to anlyse the human metabolome.
Milk is an ideal bio-fluid for metabolomics studies since it can be obtained
noninvasively, and the composition is directly reflective of genetic and environmental
factors affecting breast health, more specifically mammary tissue and the milk
secreting cells (lactocytes). With respect to lactation, nipple pain and mastitis have
been found to produce biochemical changes in human milk including an increase in
sodium and protein concentrations. As a result of cellular changes such as increased
neutrophil count and activation of leukocytes causing them to extravasate into the
milk at the site of inflammation (Michie et al., 2003; Hassiotou et al., 2013).
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1.7.4

Targeted metabolomics

Bacterial and fungal metabolites can be used to detect and quantify bacteria and fungi
in a solution. Furthermore metabolites only present in specific species of bacteria
could allow more specific detection of target bacteria. GC-MS has successfully been
used to identify biomarkers in complex matrixes (e.g. blood and urine) and provides
high sensitivity and detection of markers even when present at nanogram levels
(Sebastian & Larsson, 2003).

1.7.5

Summary

Research has already begun to identify the milk metabolome, however these studies
lack focus on nipple pain and mastitis and their causative agents. There has been no
untargeted analysis of metabolites linked to mastitis that may be present in the milk
during a mastitis event. Identification of changes to the metabolome in the presence of
nipple pain or mastitis, if established, could be a useful tool in clinical diagnosis and
determining the underlying problem. Therefore, metabolite profiling has the potential
to provide a diagnostic tool for the early identification of inflammatory processes
contributing to nipple pain and mastitis. Targeted metabolomics could be used to
identify the presence of specific metabolites, such as bacterial metabolites, to
determine the influence of bacteria and identify the presence of bacteria as a possible
cause of nipple pain and mastitis. This research provides an investigative model for
the current work in the human metabolome and provides direction for more specific
analysis following the optimisation of untargeted metabolite profiling.
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1.8 Aims and Hypothesis
1.8.1

Project outline

This project aims to use current knowledge of human and bovine milk together with
traditional microbial and biochemical methods to identify where new generation
methods can be useful to gain further knowledge into breast milk composition and the
effect of infection and inflammation. Metabolomics using gas chromatography mass
spectrometry (GCMS) will allow metabolite profiling of human and bovine milk
samples and the identification of possible biomarkers for nipple pain that could
potentially develop into mastitis.

1.8.2

Hypothesis

The presence of persistent nipple pain, with and without evidence of trauma, in
lactating women will result in changes in human milk metabolite profile due to
infection and inflammation compared to asymptomatic women (controls).

1.8.3

Aims

Aim 1: To identify the presence of bacteria and fungi using conventional culture
techniques, and to quantify bacteria and fungi detected.

Aim 2: To measure the effects of nipple pain and trauma on the paracellular pathway
of the breast by measurement of the sodium and potassium concentration and
ratio in human and bovine milk.
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Aim 3: To optimise methodology for GC-MS (untargeted) measurement of
metabolites in human milk and bovine milk.

Aim 4: To identify differences in the metabolic profile of human milk in mothers with
nipple pain (with and without trauma) compared to healthy control mothers
(asymptomatic), using untargeted analysis.

30

2 Materials and Methods
2.1 Materials
All materials used in the methods, are presented in (the following) tables, 2.1-2.5.
Materials are separated into four tables to reflect the four sections presented in the
methods. The fifth table contains the identification of metabolite reference standards
used for metabolomic optimisation. Materials are presented with supplier and
abbreviations where possible and suppliers are arranged in the order they appear in
Methods.

Reagents were prepared using double deionized water (DDI) (supplied by The
Hartmann Human Lactation Research Group, UWA) unless stated otherwise. DDI
water was prepared with a PRELAB Classic water purification system (Ibis
Technology, Osborne Park, WA, Australia); the DDI water used for breast
sterilisation was further heat sterilised using an autoclave.
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Table 2.1

Human milk collection method, with supplier listed.

Chemical

Thermo Fisher Scientific Australia Pty. Ltd.
PDI Alcohol prep pads (70% isopropyl)
Medical and Surgical Requisites Pty Ltd, QLD, Australia
5% Chlorhexidine skin cleanser (Microshield)
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Table 2.2

Bacteriology methods, with supplier and abbreviations listed.

Chemical

Abbreviation

Pathwest Laboratory Medicine WA, Forrest House Mt Claremont, WA, Australia
5% Horse blood agar plates (PO81)
Deoxyribonuclease (DNase) agar plates (P090)
Sabouraud Dextrose agar powder (Oxoid- CM0041)
Vogel-Johnson agar plates (1347)
Yeast Extract Glucose Chloramphenicol (YGC) agar (1498)
Dichloran Rose Bengal Chlortetracycline (DRBC) agar plates (1139)
Sigma-Aldrich Pty. Ltd., Castle Hill, NSW, Australia
Mannitol Salt Phenol Red agar powder (63567)
Amber Scientific, Midvale, WA, Australia
Gram stain kit (ref#-76):

Crystal violet 0.5% stain (CV-500)

GV

Gram’s iodide solution (GI-500)

GI

Decoulourizer solution (DECL-500)

DECL

Safarin aqueous stain (SF-500)

SF

Blackaby Diagnostics, Darlington, WA, Australia
Phadebact latex kit
Thermo Fisher Scientific Australia Pty Ltd, Melbourne, VIC, Australia
Hydrochloric acid (1N) (SA48-1)

HCl
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Table 2.3

Sodium and potassium analysis, with supplier and abbreviations
listed.

Chemical

Abbreviation

Univar ®, Redmond, WA, USA
Sodium chloride (465)

NaCl

Potassium chloride (383)

KCl
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Table 2.4

Metabolomic analysis of human and bovine milk, with supplier
and abbreviations listed.

Chemical

Abbreviation

Thermo Fisher Scientific Australia Pty. Ltd., Melbourne, VIC, Australia
Methanol (LCMS grade) (A454-4)

MeOH

Water (LCMS grade) (W6-4)
Acetonitrile (A955-4)

ACN

Hexane 95% (H306-4)
Sigma-Aldrich Pty. Ltd., Castle Hill, NSW, Australia
D-Sorbitol-13C6 99% (605514)
N-Methyl-N-(trimethylsilyl) trifluoroacetamide(M7891)(394866)

MSTFA

Methoxyamine hydrochloride 98% (226904)
2-Aminoanthracene (A38800)
Ajax Finechem, Sydney, NSW, Australia
Pyridine (AJA430)
Chem Service Inc., West Chester, PA, USA
n-decane C10 (0-729) (Purity – 99.8%)
n-dodecane C12 (0-731) (Purity - 99.4%)
n-pentadecane C15 (0-2238) (Purity - 98.9%)
n-nonadecane C19 (0-2203) (Purity – 99.4%)
n-docosane C22 (0-2089) (Purity – 99.2%)
n-octacosane C28 (0-2227) (Purity- 99.5%)
n-dotriacontane C32 (0-2095) (Purity - 98.5%)
n-hexatriacontane C36 (0-2128) (Purity - 98%)
Grace Davison Discovery Sciences, Rowville, VIC, Australia
SPE bulk sorbent prevail C18 (%125474)

SPE

35

Table 2.5

List of metabolite reference standards used for metabolomic
method optimisation, with supplier listed.

Metabolite
Sigma-Aldrich Pty. Ltd., Castle Hill, NSW, Australia
L-Valine (V0500) (Purity 98%)
L- Alanine (A7627) (Purity 98%)
Glycine (241261) (Purity 99%)
L- Leucine (L8000) (Purity 98%)
L-Proline (P0380) (Purity 99%)
L-Isoleucine (I2752) (Purity 98%)
L-Norleucine (N6877) (Purity 98%)
L-Cysteine (168149) (Purity 98%)
Urea (U5378)
L-Serine (S4500) (Purity 99%)
Ethanolamine (E9508) (Purity 98%)
L-Threonine (T8625) (Purity 98%)
Succinic Acid (398055) (Purity 99%)
Putrescine (dihyrdochloride) (P7505) (Purity 98%)
L-Serine (S4500) (Purity 99%)
L-Methionine (M9625) (Purity 98%)
L-Aspartic acid (A9256) (Purity 98%)
L-Glutamic Acid (G1251) (Purity 99%)
L-Phenylalanine (P2126) (Purity 98%)
a-Ketoglutaric acid (K1750) (Purity 98.5%)
Ribitol (Adonitol) (A5502) (Purity 99%)
Citric acid (251275) (Purity 99.5%)
L-Lysine (L5501) (Purity 98%)
D-(-)-Fructose (F0127) (Purity 99%)
L-Tyrosine (W373605) (Purity 97%)
D-Mannitol (M4125) (Purity 98%)
D-Sorbitol (S1876) (Purity 98%)
Myo-inositol (I5125) (Purity 99%)
Ribose-5-phosphate (disodium salt hydrate) (83875) (Purity 99%)
L-Tryptophan (T0254) (Purity 98%)
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Table 2.6

Equipment used, with manufacturer listed.

Equipment

Medela AG, Baar, Switzerland
Symphony® breast pump and attachments
Quick Clean™ microwave bags
Corning Incorporated, Corning, NY, USA
PC-351 HOT Plate Stirrer
Getinge AB Group, Getinge, Sweden
HS4406 Steam Sterilizer (autoclave)
Forma Scientific, Inc., Marietta, OH, USA
3164 - Water Jacketed Incubator
Horiba Scientific Ltd., Kyoto, Japan
LAQUAtwin sodium ion electrode (S022)
LAQUAtwin potassium ion electrode (S030)
Crown Scientific Pty Ltd., NSW, Australia
Eppendorf Thermomixer® comfort
Microcentrifuge 5415R
IKA MS1 Works (vortex)
Bruker Daltonics, Billerica, MA, USA
450-GC Oven
Shimadzu Corporation, Kyoto, Japan
GC-MS- Shimadzu QP2010 Ultra, Kyoto, Japan
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Table 2.7

Data analysis software, with manufacturer listed.

Software

R Development Core Team
R 3.0.3 GUI 1.638 Snow Leopard build 32-bit (6660)
SpectralWorks Ltd, Cheshire, United Kingdom
AnalyzerPro 2.7.0.0
Shimadzu Corporation, Kyoto, Japan
GCMSsolution 2.61
Camo Software AS
The Unscrambler
SAS Institute Inc.
JMP 8.0.2
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2.2 Methods
2.2.1

Human sample collection

2.2.1.1 Recruitment
Mothers between the ages of 18-45 years currently breastfeeding a baby between the
age of 1-6 months were recruited. Participants were predominantly recruited through
community engagement and ongoing communication using flyers, World Wide Web
(e.g. social media) and in person promotion. Additional participants were recruited via
the Australian Breastfeeding Association (ABA), local community health nurses and
lactation consultants and through posts on the University of Western Australia
website. Mothers already participating in research studies associated with Hartmann
Human Lactation Research Group (HHLRG) under the supervision of Professor Peter
Hartmann were also invited to participate.

Mothers were supplied with a consent form and general information sheet to complete
at the time of milk collection (Appendix 2.1 and 2.2). Using the Visual Analogue
Scale (VAS) for pain intensity as described by McClellan et al. (2012) mothers were
asked to rate their pain when breastfeeding from ‘no pain’ to the ‘worst pain
imaginable’. Measured pain intensity was recorded and converted to a numerical
value between 0 and 10, 0 being no pain and 10 representing the highest level of
perceived pain.

Mothers were registered online with the HHLRG and provided with a unique
identification number. Mothers received their identification number via email which
contained a link directing them to an online questionnaire with questions relating to
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parity, infant and maternal age, medication and current health status of the mother and
infant. The questionnaire is provided in Appendix 2.3.

2.2.1.2 Human milk collection
Milk samples were collected from mothers with and without persistent nipple pain at
a single time-point. Milk samples were collected from a single breast in mothers
without nipple pain (control). Mothers with bilateral nipple pain provided a single
milk sample from the breast experiencing the greatest level of perceived pain during
breastfeeding. Mothers with unilateral nipple pain were asked to provide a sample
from the affected breast and non-affected breast; this acted as a paired control.

Participating mothers were requested not to express or breastfeed for at least 3 hours
prior to milk collection (most relevant to those presenting with unilateral nipple pain
and therefore suitable to donate both a nipple pain and control sample) to ensure the
breast was full or near full at the time of collection (Hassiotou et al, 2013), and/or
required to provide a sample from the breast that had not recently expressed. Before
collection mothers were required to adequately clean their hands (using Aqium
antibacterial hand gel) and their breast to remove skin contaminants. The breast was
washed by rinsing the nipple and surrounding skin with sterile water (DDI water that
had been sterilised by autoclave at 120 °C for 15 minutes), followed by an alcohol
wipe (70 % isopropyl alcohol) (Thermo Fisher Scientific Australia Pty Ltd.), a mild
disinfectant (chlorhexidine) (Medical and Surgical Requisites Pty Ltd) and then a
final rinse with sterile water before milk collection (Hale, Bateman, Finkelman &
Berens, 2009). The breast pump and its attachments were sterilised in Quick Clean ™
microwave sterilising bags (Medela, AG) prior to use. Participating mothers were
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fitted with a breast shield connected to a Symphony® electric breast pump (Medela
AG) and instructed to set the pump to a setting comfortable for them. A minimum of
15 ml of breast milk was collected and immediately put on ice, covered from light and
transported to the laboratory for storage.

On arrival at the laboratory the samples were gently mixed and divided into three
aliquots of 5 ml into 15 ml falcon tubes and stored at -80 °C until analysis.

For sample analysis purposes human participants were de-identified and given
reference identification numbers, mothers were labelled M01-M29 with the addition
of sample identification numbers separating the control (C01-C22) and NP (NP01NP11) participants.

2.2.1.3 Participant demographic data analysis
Analyses of participant demographics were conducted to identify differences between
control and nipple pain subgroups. Participant identification numbers and sample
identification numbers are presented in the tables in the appendix.

Demographic analysis focused on maternal age, infant age and parity. All analyses
were performed using R 3.0.3 GUI 1.638 Snow Leopard for Mac OSX (R
Development Core Team, 2011) using the base packages, and the libraries NLME
(Pinheiro, Bates, DebRoy & Sarkar, 2011) and multcomp (Hothorn, Bretz & Westfall,
2008), which were used for linear mixed modelling and multiple comparison of
means, respectively. A linear mixed effect model and linear regression (linear model)
were calculated and compared by ANOVA to determine underlying physiological
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differences between individuals. Categorical variables, including parity, were
compared using Fisher’s exact test. Summary statistics are presented as mean ± SD,
or median (IQR), or proportion. p < 0.05 was considered to be statistically significant.

2.2.2

Bovine sample collection

A set of bovine milk samples, from healthy cows (control), cows suffering from
mastitis and pooled samples from a single storage vat, were collected for comparative
purpose to be used as positive control throughout the study. Milk samples were
collected from Friesian Holstein (Black and White) dairy cows at a functional dairy in
the south west of Western Australia. Pooled milk samples were collected by removing
a 15 mL aliquot from a single storage vat prior to pasteurisation. Samples from
individual cows were collected by hand expression of 15 ml of milk into a 25 ml
falcon tube. All samples were sealed, covered from light, stored on ice and
immediately returned to Perth for storage in an -80 °C freezer.

Bovine milk samples were collected from four lactating cows, given reference
identification numbers B01-04, and the pooled bovine vat collections were labelled
V01-V02. Additionally individual bovine samples were identified by sample
identification numbers BC01-03 for bovine control samples, BM01-04 for samples
retrieved from cows with mastitis and BV01-BV02 for the two pooled bovine vat
samples.
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2.2.3

Microbial methods

2.2.3.1 Media preparation
Mannitol Salt agar
Mannitol salt phenol red agar powder (Sigma-Aldrich Pty. Ltd., Australia) 111 g/L
was prepared (in Millipore filtered double deionised distilled water). Agar solution
was sterilize by autoclave (HS4406 Steam Sterilizer) (Getinge AB Group, Sweden) at
121 °C for 15 minutes and stored in 100 mm plates (50 plates, 25 ml per plate) below
8 °C.

Sabouraud Dextrose agar
Sabouraud Dextrose agar powder (Sigma-Aldrich Pty Ltd., Australia) 65 g/L was
prepared (in Millipore filtered double deionised distilled water) and brought to boiling
point until dissolved, using a PC-351 HOT plate Stirrer (Corning Incomprated, USA).
Agar solution was sterilize by autoclaving (HS4406 Steam Sterilizer) (Getinge AB
Group, Sweden) at 121 °C for 15 minutes and poured into 100 mm plates (50 plates,
25 ml per plate) below 8 °C.

2.2.3.2 Culture
Bacterial cultures were prepared in a laminar flow hood under sterile condition as
recommended by the National Mastitis council (2012). 50 µl of each milk sample
were spread evenly on each of the following agar plates in dublicate; 5 % Horse blood
agar, Mannitol Salt agar (MSA) and Sabouraud Dextrose agar. Plates were incubated
(3164 - Water Jacketed Incubator, Forma Scientific, USA) at 37 °C for 24 ± 2 hours;
Sabouraud agar plates were incubated for an additional 96 hours.
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A colony forming unit (CFU) count was conducted to determine total CFU/ml on 5%
Horse Blood agar, MSA and Sabouraud agar. Bacterial species were identified by
Gram stain with the help of Cristina Farrar (Senior Medical Scientist at Princess
Margaret Hospital, Subiaco W.A.). S. aureus was identified based on positive latex
agglutination test (to detect the coagulase enzyme) and positive culture on DNase S.
aureus specific agar plate.

Additional agar plates Dichloran Rose Bengal Chlortetracycline (DRBC) agar and
Yeast Extract Glucose Chloramphenicol (YGC) agar (supplied by PMH) were used
for specific isolation and identification of yeast species and Vogel-Johnson agar was
used for the isolation and quantification of S. aureus following previous identification
of target species (yeast and S. aureus) on Sabouraud agar and MSA respectively. All
cultures were prepared following previously mentioned culture techniques, i.e. 50 µl
of whole milk spread evenly on the agar plate and incubated at 37 °C for 24 ± 2
hours.

2.2.3.3 Bacterial and fungal species detection through Gram stain
Traditional Gram stain technique, as adapted from the original publication of Gram
(1984) was used for microbial identification (Gram, 1884; Gephart et al., 1981). The
colony of interest was transferred by loop onto a clean glass slide and heat fixed prior
to applying a Gram stain. Using a Gram stain kit (Amber Scientific, Australia) the
slide was flooded with crystal violet solution for up to a minute, washed briefly with
distilled water and the excess water drained. Using Gram’s iodide solution the slide
was flooded again and left to sit for one minute before washing with distilled water
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and draining. Using paper towel the slide was gently blotted dry and flooded for 10
seconds with decolourizer solution followed by washing with distilled water and
draining. Lastly the slide was flooded with Safranin aqueous stain for 30 seconds. The
slide was then washed using distilled water, followed by draining and blotting dry
(being careful not to rub).

All slides were examined under an oil immersion lens and bacterial species were
identified.

2.2.3.4 S. aureus identification
2.2.3.4.1 Latex agglutination test
The latex agglutination test was conducted to confirm the presence of S. aureus using
a latex agglutination kit (Blackaby Diagnostics, Australia); following culture on blood
agar and MSA.

Once a potential culture of S. aureus was identified on an MSA plate an inoculation
loop was used to transfer a single colony to a latex agglutination card. A drop of red
latex was added and the solution was mixed thoroughly using an inoculation loop
followed by gently hand rocking the card for a further 20 seconds. Agglutination or
clumping should be instantaneous with most S. aureus strains.

2.2.3.4.2 DNase agar plate
Additionally any potential S. aureus cultures identified on MSA plates were cultured
on a DNase agar plate (supplied by Pathwest Laboratory Medicine, Australia). Using
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an inoculation loop a single colony was transferred to a DNase agar plate and spread
in a small circle on the surface of the agar. The plate was incubated (3164 - Water
Jacketed Incubator, Forma Scientific, USA) for 24 hours at 37 °C followed by the
addition of 1N HCl (Thermo Fisher Scientific Australia Pty Ltd.). The addition of
HCl precipitates DNA in the media causing cloudiness, unless the DNA has been
hydrolysed by S. aureus in which case creating a clear zone or ‘halo’ around the
growing colony occurs, which indicates positive growth for S. aureus.

2.2.3.5 Data analysis
Data analyses of CFU/ml (as determined by culture on 5% horse blood agar) was
performed using R 3.0.3 GUI 1.638 Snow Leopard for Mac OSX (R Development
Core Team, 2011) using the base packages, and the libraries NLME (Pinheiro et al.,
2011) and multcomp (Hothorn et al., 2008), which were used for linear mixed
modelling and multiple comparison of means, respectively. Summary statistics are
presented as mean ± SD of the CFU/ml and logarithmic value of the CFU/ml. A
p-value < 0.05 was considered to be statistically significant.

2.2.4

Sodium and potassium analysis

Sodium (Na+) and potassium (K+) ion analysis was based on a previous method using
ion electrodes by Fetherston, Lai and Hartmann (2006). To determine the accuracy
and reproducibility of the ion electrodes a set of concentration standards and
calibration recovery standards were prepared and analysed prior to the analyses of the
final sample set. Quality controls were used to identify unwanted variation such as the
result of preparation or instrumental error (De Livera et al., 2012). Additional
concentration standards and calibration recovery standards were analysed throughout
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the final sample set to ensure that reproducibility within ± 10 % was being
maintained.
Na+ and K+ concentration was measured using Horiba LAQUAtwin sodium ion
electrode (S022) and Horiba LAQUAtwin potassium ion electrode (S030) (Horiba
Scientific Ltd.). 300 µl from each sample was transferred by pipette onto the electrode
and the reading was recorded (mV). The sample was removed and discarded and the
electrode was washed using DDI water and dried with blotting paper and the process
repeated. This method was used for the final sample set.

2.2.4.1 Preparation of concentration standards
A total of 10 sets of 7 preparation standards of known concentration were prepared,
one set was used for method optimisation and the remainder were used for analysis of
the final sample set.

A 25mM sodium/potassium (Na/K) stock was prepared by dissolving 1.461 g/L of
NaCl (Univar ®, USA) and 1.964 g/L of KCl (Univar ®, USA) in 100 ml of (DDI)
water. Using the 25 mM stock, Na/K standards between 0.5-25 mM were prepared in
15 ml falcon tubes as per Table 2.8.

The standards were divided into 1.5 ml aliquots using 2 ml centrifuge tubes and stored
at -20 °C before use. Aliquots of the standards were used later to create a sodium and
potassium standard curve to assist with calculation of sodium and potassium ion
concentration in actual milk samples.
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Table 2.8

Preparation of sodium and potassium standards for a standard
curve.

Concentration (mM)

25mM Stock (ml)

DDI (ml)

0.5

0.2

9.8

2.5

1.0

9.0

5.0

2.0

8.0

10.0

4.0

6.0

12.5

5.0

5.0

17.5

7.0

3.0

25.0

10

0

2.2.4.2 Preparation of calibration recovery standards
A total of 10 sets of 3 calibration recovery standards was prepared, 3 sets were used
for method optimisation and the remainder were used as part of the analysis of the
final sample set.

A 15 mM Na/K stock standard was prepared in a 25 ml falcon tube by adding 12 ml
of the previously made 25 mM Na/K stock to 8 ml of DDI. Using the 15 mM Na/K
stock 10 sets (3 test tubes per set) of calibration recovery standards were dispensed in
2 ml centrifuge tubes as seen in Table 2.9. All aliquots were stored at -20°C.

Table 2.9

Preparation of calibration recovery standards.

Test tube
1

750 μl of whole milk + 750 μl of 15 mM standard

2

750 μl of whole milk + 750 μl of DDI

3

750 μl of DDI + 750 μl of 15 mM standard
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2.2.4.3 Method optimisation: recovery assay for calibration recovery standards
One full set of Na+/K+ standards (seven tubes) and three sets of calibration recovery
standards (nine tubes) were removed from the freezer and incubated at room
temperature for 5 minutes. Na+ and K+ concentrations in mV was measured and
recorded in duplicate using the previously described method (2.2.4).
A logarithmic standard curve was prepared for the Na+ and K+ concentration
standards. This was plotted on an XY graph (Figure 2.1 and Figure 2.2) and used to
determine the unknown concentrations of the calibration recovery standards.

49

Na+ Standard Curve

y = 24.486ln(x) - 78.835
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Figure 2.1

K+ Standard Curve
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50

To determine the accuracy and reproducibility of the electrodes, the calculation as
seen in Figure 2.3 was used for each set of calibration recovery standards using the
average concentration of the individual aliquot duplicates. A reproducibility of ± 10%
was considered acceptable.

[ONE (mM) – TWO (mM)]
=
1.00
=
100%
THREE (mM)
_________________________________________________________________
Example Calculation:
Tube one: 13.59 mM
Tube two: 7.05 mM
Tube three: 6.43
13.59 – 7.05
6.43

=

1.02

=

102%

Figure 2.3
Reproducibility calculations for calibration recovery standards.
Values ONE, TWO and THREE correspond with calibration recovery standards test
tubes 1, 2 and 3 in Table 3.2.
Table 2.10 illustrates the reproducibility calculated for the initial three sets of
calibration recovery standards. All sets produced reproducibility within ± 10 % and
only five measurements displayed reproducibility less than ± 5 % (represented by the
shaded cells in Table 2.10). These results were deemed satisfactory to move onto
subsequent analysis.
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Table 2.10

Reproducibility of calibration recovery standards.

Recovery set
1
2
3

Ion

Aliquot A

Aliquot B

Aliquot C

Na+

1.02

0.99

1.01

K+

1.02

1.00

1.00

Na+

0.99

0.97

1.04

K+

0.94

0.96

1.10

Na+

0.95

1.00

0.92

K+

0.94

1.07

1.02

Reproducibility of less than ± 10 % is required for each set of calibration recovery
standards.
Most samples had a % recovery less than 5 %.
Highlighted cells indicate reproducibility ≥ ± 5 %.

2.2.4.4 Measurement of Na+ and K+ ion concentration in milk
A set of concentration standards and calibration recovery standards were analysed
each day prior to milk sample analysis. The calibration recovery standards were used
to ensure reproducibility was being maintained and the concentration standards were
used to calculate a logarithmic equation used to determine the Na+/K+ concentrations
of the samples analysed on that day (total of four days of analysis).

The Na+ and K+ concentration of each milk sample was measured in mV and recorded
in duplicate using the previously described method (2.2.4.). Readings were converted
from mV to mM using the equation calculated from the sodium and potassium
standards as previously explained. Once all Na+ and K+ measurements were converted
to mM the Na+/K+ ratio was calculated [by dividing the Na+ concentration by the K+
concentration]. A Na+/K+ ratio level above 1 was considered abnormal and a sign of
inflammation or possible infection (Aryeetey et al., 2008).
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Following analysis of all milk samples and corresponding standards the equations for
all standard curves was compared to identify any differences in concentrations that
may have occurred between days (Figure 2.4 and Figure 2.5).

Comparison of Na+ Standard Curves

Volatge Output (mV)
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-80

Na: 4
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-120

+ + Conceration (mM)
Na
Na
Concentration (mM)

Figure 2.4
Comparison of Na+ standard curves.
This figure shows the reproducibility of the Na+ standard curve as measured on four
separate occasions.

Comparison of K+ Standard Curves
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Figure 2.5
Comparison of K+ standard curves.
This figure shows the reproducibility of the K+ standard curve as measured on four
separate occasions.
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2.2.4.5 Data analysis
All samples were analysed for Na+ and K+ concentration and Na+/K+ ratios were
calculated. All analyses were performed using R 3.0.3 GUI 1.638 Snow Leopard for
Mac OSX (R Development Core Team, 2011) using the base packages, and the
libraries NLME (Pinheiro et al., 2011) and multcomp (Hothorn et al., 2008), which
were used for linear mixed modelling and multiple comparison of means,
respectively. A linear mixed effect model and linear regression (linear model) were
calculated and compared by ANOVA to determine underlying physiological
differences between individuals. Summary statistics are presented as mean ± SD. A
p-value < 0.05 was considered to be statistically significant.
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2.2.5

Metabolomic profiling of human and bovine milk

Due to the complexity of human milk, together with the large variability between
individuals, and the inherent difference between milk and other biological matrices,
key components of the methods were optimised for the measurement of milk
metabolites. The components requiring optimisation were the sample volume and the
derivatisation reaction temperature.

Derivatisation allows the analysis of compounds that are not directly amenable to GC
analysis. An increased volatility is one such benefit of derivatisation, and particularly
for early eluting compounds, improved volatility can permit analysis in an otherwise
obscured chromatographic background (Gullberg, Jonsson, Nordström, Sjöström, &
Moritz, 2004). Within the literature a range of derivatisation reactions and conditions
including temperatures and derivatisation reaction times has been used previously
(Gummer, Trengove, Oliver and Solomon, 2013; Gullberg et al., 2004; Dunn et al.,
2011; Bressanello et al., 2014).

Therefore, sample preparation optimisation, namely the incubation temperature for
MSTFA derivatisation, and the optimal sample volume that can be analysed in a
single derivatising volume, was carried out prior to the analyses of the final sample
set.

2.2.5.1 Metabolite analyses
Polar metabolites were isolated from the milk using a solid phase extraction approach,
following removal of the protein content by organic solvent precipitation. The dried
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extract was then derivatised using a combination of oximation and silylation in
preparation for instrumental analysis.
Proteins were precipitated by the addition of 1.2 mL ACN, added whilst gently
mixing, and incubated at room temperature for 10 minutes. The precipitate was
pelleted by centrifuging for 20 minutes at 10°C at 16,100 g. The supernatant (1,600
µl) was transferred into a fresh 2 ml centrifuge tube and the remaining pellet
discarded. The supernatants were divided into two aliquots of 180 µl (equivalent to 50
µl of milk), which were frozen on dry ice and dried by lyophilisation. The remaining
volume was stored at -80°C.

Samples were redissolved and fractioned by SPE according to the methods of
Gummer and Trengove (Unpublished 2015). Specific details are not available due to
intellectual property issues regarding patent of this method. Briefly, the method
involves separating polar metabolites from non-polar. The polar fraction was then
dried by lyophilisation in preparation for derivatisation. The remaining non-polar
components were stored at -80°C for future studies.
Dried samples were derivatised in batches of 24, including QC samples, based on the
methods of Gummer et al. (2013), but further optimised for milk analysis (in this
thesis). A methoxyamine solution was prepared by dissolving 20 mg/ml of
methoxyamine hydrochloride (Sigma-Aldrich Pty. Ltd.) in pyridine (Ajax Finechem).
20 µl was added to each sample and agitated at 1,200 rpm for 90 minutes at 30°C
using an Eppendorf Thermomixer® Comfort (Crown Scientific Pty Ltd.). Samples
were then centrifuged in a Microcentrifuge 5415R (Crown Scientific Pty Ltd.) for one
minute at 18 °C and 16,100 g. The methoxymated sample solution was transferred to
a glass analytical vial with a glass insert followed by the addition of a 5 µl solution of
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n-alkanes C10, C12, C15, C19, C22, C28, C32, C36 (Chem Service Inc., USA), in n-hexane
(95 %) (Thermo Fisher Scientific Australia Pty Ltd) for calculation of retention
indices, and 40 µl of MSTFA (Sigma-Aldrich Pty. Ltd.). The vials were cap sealed
and gently mixed using a vortex, IKA MS1 Works (Crown Scientific Pty Ltd.), before
incubating in a 450-GC oven (Bruker Daltonics), pre-heated to 75°C, for 60 minutes.
The samples were mixed on low using a vortex, IKA MS1 Works (Crown Scientific
Pty Ltd.), at 15 minute intervals during this 60 minutes incubation period.

The vials were removed from the GC oven and set aside to rest for two hours before
analysis by GC-MS.

The samples were analysed in random order including a 20 minute methanol blank
between all samples and 60 minute methanol blank every four injections. QC samples
were used to equilibrate the system ahead of sample analysis and analysed within the
sample batch every fifth sample.

2.2.5.1.1 Milk volume optimisation for derivatisation
A series of 5 milk samples (from each of the sampling groups) were prepared in
duplicate to determine the optimal volume for milk analysis by GC-MS; one human
control, one nipple pain without trauma, one nipple pain with trauma, one bovine
control and one bovine mastitis. Two 600 µl aliquots of each sample was used and
prepared according to the protein precipitation method in 2.2.5.1. The resultant
supernatant (1,600 µl) was dispensed into a 2 ml centrifuge tube and divided into two
sets of four volumes 75, 150, 225 and 300 µl, sample volumes containing an
equivalent volume of 25, 50, 75 and 100 µl of milk, respectively. Internal standards of
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65 µl of 500 µg/ml 13C6 Sorbitol (Sigma Aldrich Pty. Ltd.) and 45 µl of 10 µg/ ml 2aminoanthracene (Sigma Aldrich Pty. Ltd.) (in water) plus 1,455 µl of water (Thermo
Scientific Australia Pty. Ltd.) was added to each sample. All samples were frozen on
dry ice and dried by lyophilisation. One of each duplicate set of four was stored at 80ºC for future studies.

Samples were redissolved and fractioned by SPE followed by derivatisation according
to the methods in 2.2.5.1 Milk samples were analysed in random order using a
Shimadzu QP2010 Ultra GC-MS (Shimadzu Corporation).

The optimal sample volume was determined with compromise between the detected
signal (peak area) of each metabolite; particularly those present in smaller
concentrations, instrument capability (efficiency and required preventive
maintenance) and the ability to dissolve the dried metabolite extracts; with data
reproducibility being the major deciding factor. The optimal equivalent volume of
milk required was determined to be 50 µl; this equivalent volume was used for all
subsequent analyses.

2.2.5.1.2 Derivatisation temperature optimisation
Metabolite reference standard mixes (mix containing 30 metabolites, Table 2.5) were
derivatised following the derivatisation method described in section 2.2.5.1, with the
exception that after the addition of MSTFA (Sigma Aldrich Pty. Ltd.) each were
incubated at one of five temperatures. The MSTFA derivatisation was assessed at the
five temperature increments, 37°C, 45°C, 60°C, 75°C and 90°C, using a 450-GC oven
(Bruker Daltonics). Two controls were also included for the 37ºC and 60ºC reaction
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temperatures, which additionally varied from the described methods in that they were
not transferred to glass vials before MSTFA addition. These two sets were heated in
an Eppendorf Thermomixer® comfort (Crown Scientific Pty Ltd.) within 2 ml tubes
for comparison to already established methods. Samples incubated within vials were
sealed by crimp cap after the addition of MSTFA and gently mixed using a vortex,
IKA MS1 Works (Crown Scientific Pty Ltd.) at 15 minute intervals during incubation.
All were prepared in triplicate.

The vials were removed from the GC oven and Thermomixer and set aside to rest for
two hours before analysis using a Shimadzu QP2010 Ultra GC-MS (Shimadzu
Corporation).

Each reference metabolite peak was de-convoluted from the total ion chromatogram
(TIC) and peak area(s) calculated using AnalyzerPro 2.7.0.0 (SpectralWorks Ltd.).
The standard deviation was calculated using the measured technical replicates, which
was plotted for each metabolite at each temperature and heating method. The optimal
temperature was determined by the reproducibility of the triplicate measurements for
each temperature. The optimal MSTFA derivatisation temperature was determined to
be 75 °C; this temperature was used for all subsequent analyses.

2.2.5.2 Preparation of the final sample set (using the optimised methodology)
Milk samples were dispensed in 500 µl volumes into 2 ml centrifuge tubes. To each
sample was added 26 µl of 500 µg/ml 13C6 Sorbitol and 60 µl of 10 µg/ml 2aminoanthracene (each in LC grade water), in a final volume of 600 µl (by the
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addition of LC-MS grade water). Each were stored at -80°C and thawed on ice prior
to preparation.

Milk samples were prepared by protein precipitation and fractioned by SPE to isolate
the polar metabolites according to methods in 2.2.5.1, with a final dried down volume
equivalent to 50 µl of milk. Dried samples were derivatised according to the method
in 2.2.5.1. prior to analysis using a Shimadzu QP2010 Ultra GC-MS (Shimadzu
Corporation).

For the purposes of quality control (QC), a second set of 500 µl aliquots was removed
from the -80°C freezer and pooled by combining 175 µl from each of the 42 samples
in a 10 ml falcon tube, followed by gently mixing using a vortex, IKA MS1 Works
(Crown Scientific Pty Ltd.). The pooled QC milk was dispensed and prepared
randomised among the samples described above.

2.2.5.3 Instrumentation and data acquisition
GC-MS analysis was carried out using a Shimadzu QP2010 Ultra GC-MS (Shimadzu
Corporation, Kyoto, Japan) injected with 1µl of derivatised milk metabolites. The
GC-MS was fitted with a FactorFour VF-5ms capillary column (30m x 0.25mm x
0.25µm + 10m EZ-Guard; Agilent, Santa Clara USA). The injection inlet temperature
was set to 230 °C, with an interface temperature of 300 °C, and an ion source
temperature of 230 °C. Helium was selected as the carrier gas and set to flow between
0.8 and 1.0 ml min-1. Prior to sample injection the inlet pressure was adjusted to elute
mannitol (6-TMS) at 30.6 minutes. The temperature gradient commenced at an initial
temperature of 70°C, increasing at 1°C per minute for 5 minutes, then changing to an
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oven ramp rate of 5.6 °C min-1 with a 10 minute hold at the final maximum
temperature of 320°C. Ionisation occurred by electron ionization (EI) at 70 eV. The
mass spectrometer was operated in scan mode in the range m/z 40 – 600, at a scan rate
of 5,600 amu sec-1. For selected ion monitoring (SIM), ions were scanned at 0.38
second intervals.

2.2.5.4 Data analysis
GC-MSsolutions 2.61 (Shimadzu Corporation, Kyoto, Japan) was used to acquire and
analyse the data post GC-MS metabolomic analysis. AnalyzerPro 2.7.0.0
(SpectralWorks Ltd.) was used for deconvolution. Appropriate qualifier and quantifier
ions were determined from the MS and the full scan spectra searched again against the
in house metabolite library and the already predetermined database (a list of tentative
metabolite identifications compiled during method optimisation of the sample
volume) of metabolite identities, for relative quantitation using the peak area of the
analyte.

2.2.5.5 Data processing and interpretation
For the method optimisations, analyte peak areas were interrogated using JMP 8.0.2
(SAS Institute Inc.). For the metabolomics analyses, peak areas were normalised to
the internal standard, 13C6 sorbitol, and scaled to the median intensity (De Livera et
al., 2012), range scaled and log transformed (log10(x + 1) using The Unscrambler
(Camo) software. Principal component analysis (PCA) was used to model the
transformed data and PCA correlation loadings calculated using The Unscrambler
(Camo).
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3 Results
3.1 Human study population
Human milk samples were donated by 29 mothers from the Perth metropolitan area
and its surrounds as well as the South West Region of Western Australia spanning
222 km (including Capel, Australind, Harvey and Bunbury) (Figure 3.1).

Figure 3.1
Sample collection area.
Where stars indicate locations of sample collection.
Reproduced from Google Maps (2015).

Milk samples were collected from women who had no pain (control group) and those
with nipple pain (nipple pain group). The control group (CG) contained only mothers
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who were experiencing pain-free breastfeeding and were used as the ‘healthy’
baseline for comparison with nipple pain samples. Nipple pain (NP) samples were
collected from mothers who were experiencing persistent nipple pain during
breastfeeding, determined by the perceived pain level during breastfeeding at the time
of collection. Additionally participants with nipple pain were assessed for nipple
trauma and breast changes (including abscess, broken nipple skin and suction lesions)
and further divided into two subgroups; persistent nipple pain with no visible trauma
(PG) and nipple pain with visible trauma (TG). Presence of trauma together with
perceived pain levels were used as a general measure of breast health and potential
damage to mammary tissue.

There were 4 mothers who were experiencing nipple pain in only one breast. These
mothers donated samples from both breasts and provided both a nipple pain and a
control sample. Three were in the Nipple Pain group (PG) and 1 was in the Trauma
Group (TG).

All mothers were non-smokers during lactation and only one reported taking
medication prior to sample collection. Mothers with infants outside the 1-6 month age
(4-24 weeks) requirement were excluded from this study.

3.1.1

Sample demographics

A summary of all sample demographics is shown below in Table 3.1 (full
demographic data set in Appendix 3.1). The mean age of the 29 mothers was 31.82
years (± 5.21) with a range of 22.2-40.8 years. Mothers in the NP group were on
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average 2.86 years older than the CG (p=0.16), however there was no significant
difference in maternal age between the CG and NP groups or subgroups.

Seventeen mothers reported the gestational age of their infant; of these mothers the
mean gestational age was 39 weeks (median=39) with a range of 37 – 41 weeks.
Of the 29 infants, 11 were female and 18 were male.

The average age of the 29 infants in the study was 13.75 weeks (± 7.42) with a range
of 4.6-26.1 weeks. The infant age in the NP group was an average 6.94 weeks
younger than the CG group (p=0.01). The TG subgroup had the youngest mean infant
age (9.02 ± 7.70 weeks) and was an average of 7.36 weeks younger than the CG
(p=0.04) (Table 3.1). There was no significant difference in infant age between the
PG and TG subgroups (p=0.98).

Of the 29 mothers 17 were multiparous; 13 had 2 children, 3 mothers had 3 children
and only 1 had 4 children. There was no significant difference of parity between
nipple pain subgroups.

3.1.2

Pain assessment

Using the Visual Analogue Scale (VAS) for pain intensity as described by McClellan
et al. (2012), mothers with nipple pain were asked to rate their pain when
breastfeeding from ‘no pain’ to the ‘worst pain imaginable’. Pain intensity was
converted to a numerical value between 0 and 10, 0 being no pain and 10 representing
the highest level of perceived pain. The control mothers (n=22) all reported a pain
level of 0 during breastfeeding. Of the 11 mothers in the NP group, 6 mothers
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reported a pain level of 5 or higher, with the 3 highest pain scores (10, 8, 8) reported
from mothers experiencing persistent nipple pain with no visible trauma. Mean and
SD of the PG and TG subgroups was 5.83 (± 3.25) and 5.0 (±1.30) respectively. There
was no significant difference in pain score between the two nipple pain subgroups
(Table 3.1).

3.1.3

Medication

Participants were asked to document any medication they were taking at the time of
collection. Some drugs have the potential to alter the transport processes in the
mammary gland directly or by altering metabolism or normal developmental
processes, which can directly affect the milk metabolome irrespective of patient
health and breast pathology. Of the 29 mothers, only one mother (M18) reported
taking an antibiotic at the time of collection; M18 was being treated for unilateral
nipple pain without evidence of trauma (PG).
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Table 3.1

Characteristics of infants and mothers in control group and nipple pain subgroups.
Control Group

Nipple Pain

Nipple Pain

(CG)

(PG)

(TG)

n = 18

n =6

n=5

Characteristic

All
n = 29

p-value

Maternal Age (years)

30.73 (± 5.50)

33.43 (± 5.50)

33.79 (± 3.13)

31.82 (± 5.21)

0.37

Infant Age (weeks)

16.38 (± 6.83)

9.80 (± 6.00)

9.02 (± 7.70)*

13.75 (± 7.42)

0.43

Parity (n)

2 (1, 3)

1 (1, 4)

2 (1, 2)

2 (1, 4)

0.07

Pain (1-10)

0

5.83 (± 3.25)

5.2 (± 1.30)

5.55 (± 2.46)

-

Antibiotics (n)

0

1

0

1

-

Paired Samples (n)

-

3

1

4

-

Paired samples denote those where the mother also donated a control sample; mothers who donated both control and nipple pain samples are
counted only in their relevant nipple pain subcategory.
Maternal age, infant age and perceived pain levels (nipple pain mothers only) are presented as a mean (± SD).
Parity is presented as median (IQR).
P-value is ANOVA (continuous) or Fisher’s exact test (categorical) comparison of all three groups. Significant differences between pain groups
and control (reference) are indicated as: * = p<0.05.
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3.2 Bovine study population
Seven bovine milk samples were collected from 4 lactating cows. Control and mastitis
samples were collected from the same cow when possible; i.e. when only a quarter or
more was presenting with mastitis, not the entire udder (Table 3.2). Each cow
supplied up to three milk samples. Three control samples were collected from the
quarters of three cows that did not appear to be suffering from mastitis at the time of
collection, including one colostrum sample collected from a cow shortly after
parturition. Four milk samples were collected from the quarters of three cows
suffering from mastitis, one of which has been treated with Clavulox, an amoxicillin
based penicillin antibiotic administered by direct injection into the affected quarter.

Two pooled milk samples were collected from a single storage vat prior to heat
pasteurisation.

Table 3.2

Distribution of bovine milk samples
Samples

Treated (w/penicillin)

Untreated

(n)

(n)

(n)

Control

3

-

-

Mastitis

4

1

3

Test Group
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3.3 Microbe assessment results
Traditionally human milk has been cultured on a selection of selective and differential
media to determine bacterial abundance and species composition. Australian milk
banks, which follow United Kingdom guidelines for operating human milk banks,
require all human milk to undergo microbial culture on 5% horse blood agar and
CLED agar plates before and after heat pasteurisation (Hartmann et al., 2007).
Microbial testing is conducted for the identification and quantification (CFU/ml) of
pathogenic organisms. Australian human milk banks standards require that donations
do not contain enterococci, Enterobacteriaceae or any bacterial pathogen capable of
producing heat-stable enterotoxins. Samples with confluent microbial growth
exceeding 105 CFU/ml are deemed unacceptable for milk bank use (Hartmann et al.,
2007).

S. aureus has traditionally been considered the most common etiological cause of
nipple pain and mastitis, with recent studies also identifying coagulase negative
staphylococcus (such as S. epidermidis) as being a possible factor in the development
of breast pain and mastitis (Amir et al., 2011). Additionally the presence of Candida
albicans and the development of breast thrush have been associated with breast and
nipple pain in breastfeeding mothers (Brent, 2001).

For the purpose of this study three main media types together with traditional
microbial analysis were used for primary identification and quantification of
microbial and fungal organisms.
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i.

5% Horse Blood agar: A non-selective media suitable for all microbial growth and
quantification of microbial species in CFU/ml.

ii.

Mannitol Salt agar (MSA): A selective media for the isolation of staphylococci
growth with the addition of a colour indicator differential for S. aureus.

iii.

Sabouraud Dextrose agar: A selective medium used for the isolation and
quantification of fungal species

Secondary microbial cultures were conducted using Vogel-Johnson agar to confirm
identification of S. aureus. Additional subcultures on Yeast Extract Glucose
Chloramphenicol (YGC) agar and Yeast Dichloran Rose Bengal Chlortetracycline
(DRBC) agar were used to confirm the identification of yeast on primary agar
cultures.

Gram stain techniques were used to determine the identification of bacterial and
fungal species. Additionally a latex agglutination test was used to confirm the
identification of S. aureus on primary agar cultures following species detection by
Gram stain.

Analysis of microbial organisms was used to identify possible causative agents
contributing to persistent nipple pain with and without visible trauma.
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3.3.1

Quantification of microorganisms

Microorganism growth was quantified and reported in CFU/ml, on 5% horse blood
agar. Fungal and bacterial colonies were included in this quantification. The full data
set is presented in Appendix 3.3. An average CFU/ml and standard deviation for each
group was calculated (Table 3.3). The data was plotted to visualise spread and
identify outliers (Figure 3.2). Subsequent culture on specific agars was used to
confirm the identity of the organism present in primary cultures.

Of the 22 human control samples 21 produced positive culture on 5% horse blood
agar, with a mean colony count of 1 623 CFU/ml (± 4 099). One sample had no
growth. All of the samples in the nipple pain with trauma (TG) subgroup cultured
positive on 5% horse blood agar. The TG samples showed the highest bacterial counts
of the human participants; the mean CFU was 2 778 CFU/ml (± 5 265). All of the
samples in the persistent nipple pain without evidence of trauma (PG) subgroup
displayed positive culture on 5% horse blood agar. The PG group produced the lowest
bacterial count with a mean CFU of 440 CFU/ml (± 289). The combined mean CFU
for the nipple pain group was 1 503 CFU/ml (± 3 494). There was no statistical
significance between groups (p=0.55).

All bovine samples (n=9) cultured positive on 5% horse blood agar with a combined
mean CFU of 11 098 CFU (± 540). The bovine mastitis samples (BM) (n=4) had a
mean CFU of 2 173 (± 2775), higher than the bovine control group (BC) (n=3) with a
mean CFU of 473 CFU/ml (± 519). The pooled bovine samples (BP) (n=2) (collected
from a single storage vat) displayed the most abundant microbial growth with a
combined CFU of 44 885 CFU/ml (± 13 584).
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As a result of the small sample size the log form of the CFU/ml was calculated to
scale the data and remove the influence of outliers (Figure 3.2, Table 3.3). Figure 3.2
illustrates the large variation in CFU/ml of the human control samples. Despite
individual control samples having the samples with the largest CFU/ml the log of the

Log
of CFU/ml
Log$of$CFU/ml$

CFU/ml is lowest in the control group as indicated by black markers, Figure 3.2.

!!!!!!!!CG!!
CG

!!!!!!!!!!!PG!!!!!!!!!
!!!!!!!!!!!!!TG!
PG
TG

Sub.$group$
Sub-Group
Figure 3.2
Log of the CFU/ml in human whole milk cultured on blood agar.
Individual sample counts are represented as triangle. The mean of each group is
represented by a black bar.
(CG; human milk, control samples, PG; human milk, persistent nipple pain without
trauma, TG; human milk, persistent nipple pain with evidence of trauma.

71

Table 3.3

CFU/ml

Log of CFU/ml

Number of microorganisms in human and bovine whole milk samples from blood agar cultures.
Control Group

Nipple Pain

Nipple Pain

(CG)

(PG)

(TG)

n = 22

n =6

n=5

1 623 (± 4 099)

440 (± 289)

2 778 (± 5 265)

1 583 (± 3 853)

473 (± 519)

2.37 (± 0.98)

2.45 (± 0.60)

2.86 (± 0.76)

2.48 (± 0.88)

2.37 (± 0.98)

All
n = 33

Bovine

Bovine

Control

Mastitis

n=3

n=4

All
n=9

2 173 (± 2 775) 1 357 (± 1 833)

2.64 (± 0.68)

2.48 (± 0.88)

CFU/ml and log of CFU/ml are presented as mean ± SD.
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3.3.2

Identification of microorganisms

Following microorganism quantification on 5% blood agar, bacterial and fungal
species were identified by Gram stain. Gram staining and oil immersion microscopy
identified bacterial and fungal species. Specific identification of bacteria and yeast
species was made by use of selective media.

3.3.2.1 5% Horse blood agar
5% horse blood agar is an enriched growth medium containing a variety of complex
nutrients suitable for the growth of most bacterial and fungal species and the detection
of haemolytic activity. Blood agar is often used to identify haemolytic streptococcus.

Blood agar culture of human and bovine milk samples resulted in cultures of a variety
of morphologies and species were identified based on morphology and Gram stain. S.
aureus was only identified in one human sample. S. aureus was identified in one
bovine sample and both pooled bovine vat samples.

Mothers presenting with unilateral nipple pain supplied a sample from their affected
and unaffected breast. Figure 3.3 is an example of a mother (M18) who was
experiencing persistent nipple pain without evidence of trauma in one breast. Pictured
are blood agar cultures of the control and nipple pain milk samples she provided.
Plate A is a blood agar culture of milk from her non-affected breast (control) and
Plate B is a blood agar culture of milk from the affected breast. Plate A indicates no
growth of pathogenic microorganisms. Two bacterial species were identified,
Corynebacterim diphtheria (blue circles) and CNS (white circles). Both species are
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commonly found in human and bovine milk, CNS in particular was found in 91 % of
the human milk samples in this study. A blood agar culture of the donor’s affected
breast (Plate B), which was experiencing persistent nipple pain without visible trauma
identified 82 % S. aureus colonies with 18 % other species (predominately CNS).
This is the only human milk sample where S. aureus was detected. Fungi were not
identified in any human milk samples.

Figure 3.3
Blood agar cultures of human milk, control and nipple pain.
Plate A is a culture of a control sample and Plate B a culture of a nipple pain sample,
which were collected from a single mother who was experiencing unilateral nipple
pain (M18). Plate A: Blue circle; Corynebacterim diphtheria ssp. and white circle;
strains of CNS. Plate B: Yellow circle; S. aureus.
Organisms most likely thought to cause pain such as yeast and Streptococcus ssp.
were found only in pooled bovine vat samples (Figure 3.4 and 3.5, respectively) and
identified using Gram stain techniques.
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Figure 3.4
Blood agar culture and Gram stain of a bovine vat sample (BV02).
The purple circle indicates a yeast colony as presented in the Gram stain on the right.

Figure 3. 5
Blood agar culture and Gram stain of a bovine vat sample (BV01).
The green circle indicates enlarged streptococcus colonies as presented in the Gram
stain on the right.
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3.3.2.2 Mannitol salt agar
All samples were cultured on MSA to confirm the presence of S. aureus and to verify
if S. aureus growth was restricted or overlooked on primary agar cultures, on 5%
blood agar. MSA is a selective media for Gram-negative bacteria and staphylococci,
but more specifically for the selective identification of S. aureus. MSA contains the
pH indicator phenol red for the specific detection of S. aureus, which causes the agar
to turn yellow (Figure 3.6). S. aureus was identified in one human milk sample which
was donated by a mother experiencing unilateral persistent nipple pain with no trauma
(M18), a bovine sample from a cow presenting with mastitis which had not been
treated with antibiotics (BM01), and both pooled vat samples (BV01/02).

Figure 3.6.

MSA culture and Gram stain of a human milk sample from a
mother (M18) experiencing persistent nipple pain (PG).
The culture was 100% S. aureus colonies (360 CFU/ml). B: Gram stain of S. aureus;
colony indicated by the black circle in image A.
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3.3.2.3 Vogel-Johnson agar
Samples previously identified to contain S. aureus growth were cultured on VogelJohnston agar to confirm the presence of S. aureus and to ensure S. aureus growth
wasn’t restricted or overlooked on 5% horse blood agar or MSA cultures.
Vogel-Johnson is selective for coagulase positive, mannitol fermenting
staphylococcus and thus is used for the clinical identification of S. aureus. S. aureus
begin to appear after 24 hours of incubation and form characteristic black colonies
(Figure 3.7). S. aureus was positively identified in one human milk sample (M18),
donated by a mother suffering unilateral persistent nipple pain without visible trauma
(Figure 3.7). Additionally S. aureus was identified in one individual bovine sample
(BM01), collected from a cow presenting with mastitis and both pooled bovine vat
samples (BV01 and BV02) (Figure 3.7).
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Figure 3.7
Vogel Johnson cultures of human and bovine milk samples.
Plate A is a culture of a human milk sample from a mother with persistent nipple pain
without trauma (M18), Plate B is a culture of a bovine milk sample from a cow
suffering from mastitis (BM01) and Plates C & D are cultures from each of the bovine
vat samples (BV01 & BV02).
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3.3.2.4 S. aureus specific DNase agar plate
The DNase agar plate was also used to positively identify S. aureus. The microbe is
able to use the DNA in the agar as a source of carbon and energy for growth. This is
accomplished by the use of a DNase enzyme which is specific for S. aureus. The
presence of a clear halo surrounding the targeted colony indicates a positive test for S.
aureus, as shown in Figure 3.8. The presence of S. aureus was confirmed in one
human milk sample (NP02) collected from a mother in the PG group and 3 bovine
samples, one individual bovine sample (BM01) and both pooled bovine vat samples
(BV01 and BV02).

Figure 3.8
DNase agar plate used for the identification of S. aureus.
The sample shown on the left is from a mother presenting with nipple pain with no
trauma. This sample shows a distinct halo around the colony and indicates a positive
test for S. aureus; the sample on the right is a negative control.
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3.3.2.5 Latex agglutination test
Gram staining and microscopy under oil immersion was used to confirm the
identification S. aureus prior to employing the latex agglutination test. The latex
agglutination test was used to confirm the presence of S. aureus via the detection of
the coagulase enzyme in the microorganism. Coagulase present in the sample
interacts with the latex particles and produces visible agglutination (Figure 3.9C). The
latex agglutination test was used in conjunction with MSA, Vogel-Johnson agar and
S. aureus specific DNase agar to confirm definitively the presence of S. aureus. It was
confirmed that one human milk sample (NP02) contained S. aureus and three bovine
samples, one individual (BM01) and both pooled bovine vat samples (BV01 and
BV02) were also confirmed to contain S. aureus. No additional sample tested positive
for S. aureus growth.

Figure 3.9
The Latex agglutination test for the detection of S. aureus.
Position C on the oxoid card indicates a positive result for S. aureus; in a sample
from a mother experiencing persistent nipple pain with no visible trauma.
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3.3.3

Fungal species identification

Following the identification and quantification of microorganisms on 5% horse blood
agar, all whole milk samples were cultured on Sabouraud agar for the identification and
quantification of fungal species. Following the identification of fungal species on
Sabouraud agar, select whole milk samples were cultured on Yeast Extract Glucose
Chloramphenicol (YGC) agar and Dichloran Rose Bengal Chlortetracycline (DRBC)
agar to confirm the presence of fungal species.

3.3.3.1 Sabouraud Agar
Sabouraud agar was used for the identification of fungal species, more specifically to
determine the presence of any Candida ssp. often thought to cause breast pathology.
No human milk sample cultured positive for the growth of any fungal species. The
pooled bovine vat samples (BV01 and BV02) where the only samples to culture
positive for fungal species (Figure 3.10).

Figure 3.10 Sabouraud agar culture and Gram stain of a bovine milk sample.
The bovine milk sample (BV02) was collected from a storage vat prior to
pasteurisation. A: Black circles indicate yeast colonies. B: Gram stain of yeast
colony.
81

3.3.3.2 Yeast Extract Glucose Chloramphenicol (YGC) agar and Dichloran Rose
Bengal Chlortetracycline (DRBC) agar
YGC and DRBC agar are selective for the growth of fungi and contains
chloramphenicol to inhibit the growth of accompanying bacterial species. YGC and
DRBC agar are used for the isolation and quantification of yeast. Bovine vat samples
(BV01/B02) were positive for the growth of yeast. Figure 3.11 are YGC and DRBC
cultures of BV01 and illustrate positive growth of yeast as indicated by the black
circles. No human samples were positive for yeast on YGC or DRBC agar.

Figure 3.11

YGC and DRBC agar cultures of a single pooled bovine vat
sample (BV01).
The bovine milk sample was collected from a storage vat prior to pasteurisation.
A: YGC agar culture; The black circle indicates a yeast colony. B: DRBC agar
culture; Black circles indicate yeast colonies.
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3.3.4

Microbial diversity

The following microorganisms were positively identified: Coagulase negative
staphylococcus ssp., Corynebacterium diphtheria, S. aureus, Micrococcus ssp.,
Streptococcus ssp., Bacillus ssp. and yeast ssp. A summary of the distribution of
bacterial and fungal species identified in the human and bovine samples are presented
in Table 3.4.

S. aureus was only identified in one human sample, from the PG (subgroup), and one
bovine sample, from a cow with untreated mastitis, and both pooled bovine vat
samples collected from the storage vat prior to heat pasteurisation. Only the pooled
bovine vat samples displayed growth of Streptococcus ssp. and yeast.

Table 3.4
Group
CG

Distribution of bacterial and fungal species between groups.
Microorganism species identified
Coagulase negative staphylococcus ssp., Corynebacterium diphtheria
ssp. and Bacillus ssp.

PG

Coagulase negative staphylococcus ssp., Corynebacterium diphtheria
ssp, S. aureus, Micrococcus ssp.

TG

Coagulase negative staphylococcus ssp., Corynebacterium diphtheria
ssp, Micrococcus ssp.

BC

Coagulase negative staphylococcus ssp., Corynebacterium diphtheria ssp
and Bacillus ssp.

BM

Coagulase negative staphylococcus, ssp., Corynebacterium diphtheria
ssp, S. aureus, Micrococcus ssp and Bacillus ssp.

BP

Coagulase negative staphylococcus ssp., Corynebacterium diphtheria
ssp, S. aureus, Micrococcus ssp, Streptococcus ssp., Bacillus ssp and
yeast ssp.

The table is divided into human and bovine subgroups.
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3.4 Sodium and potassium ion analysis
Elevated sodium ion concentration in milk has been used previously as a measure of
breast health and damage to mammary tissue (Filteau et al., 1999). However, as milk
composition is highly variable between individuals it was proposed that potassium
concentration be used as a baseline and a sodium to potassium ratio used as a new
measure of breast pathology (Aryeetey et al., 2008). This study measured the sodium
and potassium concentration in all samples and determined the sodium/potassium
ratio, an elevated sodium to potassium ratio above 1.0 was considered indicative of
infection and mastitis (Aryeetey et al., 2008).

3.4.1 Measurement of sodium and potassium in human and bovine milk
samples
The sodium (Na+) and potassium (K+) ion concentrations and sodium to potassium
ratio (Na+/K+) was recorded for the duplicates of all human and bovine samples. The
mean (± SD) for Na+ and K+ concentration and Na+/K+ ratio were calculated for the
human control and nipple pain subgroups, and is shown in Table 3.5 (complete
sample set in Appendix 3.4).

The TG subgroup had a mean Na+ concentration of 8.01 mM (± 2.40), which was on
average 2.23 mM (± 0.93) higher than the PG group (p=0.056). The TG had a
significantly higher Na+ concentration than the control group which was on average
3.77 mM (± 0.76) lower than the TG subgroup (p<0.001).
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Analysis of the K+ concentration in milk found that both the PG and TG subgroups
had a higher mean concentration than the control group, 13.55 mM and 14.45 mM vs.
12.72 mM, respectively. However, there was no statistically significant difference
between the control and nipple pain group or subgroups (p=0.053).

Calculation of the Na+/K+ ratio found that the TG subgroup had the highest mean ratio
(0.55 ± 0.15), which was significantly higher than the control group (0.34 ± 0.09)
(p<0.001). The mean ratio for the TG subgroup was higher than the PG subgroup
(0.43 ± 0.11), however no significant difference in Na+/K+ ratio was found between
the subgroups (p=0.10).

85

Table 3.5

Summary of Na+ and K+ concentrations and Na+/K+ ratio recorded for human milk samples.
Control Group

Nipple pain

Nipple Pain

(CG)

(PG)

(TG)

(n=22)

(n=6)

(n=5)

Na+ (mM)

4.32 (±1.18)

5.81 (±1.94)*

08.04 (±2.40) †

5.15 (±2.02)

0.0001

K+ (mM)

12.72 (±1.23)

13.55 (±1.98)

14.45 (±1.64)***

13.13(±1.54)

0.0530

Na+/K+ ratio

0.34 (±0.09)

0.43 (±0.11)

00.55 (±0.15) †

0.39 (±0.13)

0.0005

All
(n=33)

p-value

P-value calculated by ANOVA (continuous) comparison between all three groups. Significant differences between pain groups and control
(reference) are indicated as: * = P<0.05, † = P<0.001.
Data are presented as mean ± SD.
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Despite the TG (0.55 ± 0.15) and PG (0.43 ± 0.11) subgroups displaying a higher
mean Na+/K+ ratio than the control group (0.34 ± 0.09), no sample had an elevated
ratio above one, a cut off previously considered to be indicative of infection (Figure
3.12). The highest Na+/K+ ratio was 0.811 recorded for M26/NP07 in the TG
subgroup.
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Figure 3.12 Box plots of Na+ and K+ concentration and Na+/K+ ratio.
Samples are shown in groups (CG: control, PG: nipple pain and TG: nipple pain with
trauma subgroup).
Box plots illustrating median, quartiles, range and outliers (°).

The mean Na+ concentration for the bovine samples (n=9) was 21.63 mM (± 11.44).
The bovine control group (n=3) had a mean Na+ concentration of 16.86 mM (± 7.4)
and the bovine mastitis group had a Na+ concentration of 30.26 mM (± 11.07) with
the highest Na+ concentration measured for a cow with untreated mastitis (45.48
mM). The two vat samples had an average Na+ concentration of 11.54 mM (± 0.01).
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The mean K+ concentration for the bovine group (n=9) was 21.75 mM (± 4.29). The
mean K+ concentration for the bovine control samples was 23.68 mM (± 2.36), which
was higher than the bovine mastitis samples (19.08 ± 5.29 mM). The two vat samples
had an average K+ concentration of 24.21 mM (± 0.22).

The average Na+/K+ ratio for the bovine samples (n=9) was 1.16 (± 1.0). The bovine
control group had a mean Na+/K+ ratio of 0.73 (± 0.34). The bovine mastitis group
had the highest mean ratio (1.82 ± 1.22); a cow with untreated mastitis had the highest
ratio (3.56). A summary of the results are shown in Table 3.6.

Table 3.6

Summary of Na+ and K+ concentration and Na+/K+ ratio recorded
for Bovine milk samples.
Control

Mastitis

Vat

All

(n=3)

(n=4)

(n=2)

(n=9)

Na+ (mM)

16.86 (± 7.4)

30.36 (± 11.07)

011.54 (± 0.02)

21.63 (± 11.44)

K+ (mM)

23.68 (± 2.36)

19.08(± 5.29)

24.21 (± 0.22) *

21.75 (± 4.49)

Na+/K+ ratio

0.73 (± 0.34)

1.83 (± 1.22)

00.48 (± 0.004)

1.16 (± 1.0)

Data is shown as mean (± SD).
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The human and bovine samples were plotted together to identify trends in the data
(Figure 3.13). The human samples were plotted as box plots for the control and nipple
pain groups, the bovine samples are indicated by red stars. It is important to note that
only the Na+/K+ ratio is comparable. Figure 3.13 identifies that both the human nipple
pain and bovine mastitis samples have an elevated Na+/K+ ratio.
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Box plots of Na+ and K+ concentration and Na+/K+ ratio for human
milk samples, with individual bovine values.

Box plots illustrating median, quartiles and range.
Human samples are shown in control and pain groups.
Individual bovine samples are represented by red stars (*); milk samples retrieved
from animals with mastitis are represented as part of the ‘pain’ category.
Pooled bovine vat samples are excluded from this figure.
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3.5 Metabolomics methods optimisation
Due to the complex nature of human milk and the large variability between
individuals it is important to develop methodology that allows the unbiased analysis
of as many milk metabolites as are amenable to the analytical technique employed,
whilst eliminating any unnecessary preparation steps and reducing the addition of
human and experimental error. Therefore, optimisation of a number of experimental
conditions was required. These included the temperature of derivitisation and the
volume of sample for analysis.

3.5.1 Sample volume optimisation
Optimisation of the sample volume required for analysis was necessary to assess the
dynamic range in concentration of the measured metabolites of human milk, and to
identify a volume that would not overload the instrument, while still being large
enough to detect metabolites present at the lower concentrations.

Human and bovine milk volumes of 25 µl, 50 µl, 75 µl and 100 µl were tested to
determine the maximum volume of milk that could be analysed in a single
derivatising volume, using the previously described method of preparation. 13C6
sorbitol was added to each sample at the same concentration, regardless of the milk
volume being tested. The alkanes were also added at a consistent volume. These
internal standards allowed a comparison of the reproducibility (calculated as %RSD)
of the measured signal(s) within an increasingly more concentrated sample matrix
(namely, 25 µl through to 100 µl equivalent milk volumes).
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The relative standard deviation (%RSD) of the 13C6 labelled D-sorbitol was calculated
for the sample set (n=5) and pooled QCs for each test volume (Table 7.1). The 50 µl
test volume had the highest reproducibility for this internal standard, with a %RSD of
10.56 %. The 75 µl and 100 µl volumes had a reproducibility of 36.32 % and 40.02 %
respectively, much higher than the 30% RSD which is commonly deemed acceptable
for biological samples (Dunn et al., 2011; Edmands, Barupal and Scalbert, 2014) and
less than the 20 % RSD deemed acceptable by the Food and Drugs Administration
guidelines for biomarker studies (Kirwan, Broadhurst, Davidson & Viant, 2013). This
is likely due to the sample preparation inconsistencies (as noted during preparation) of
the 75 µl and 100 µl volumes, many of which appeared opaque and presented with
precipitation, which suggests the larger sample volumes were not completely
dissolved in the derivatisation solvents at the higher sample concentrations.

To assess if the chosen internal standard, 13C6 -D-sorbitol, would likely be able to
account for signal fluctuations across the chromatogram when applied to the greater
metabolomics study, the 13C6 -D-sorbitol was compared against the measured signal
of the added alkanes. The peak intensity of n-alkanes C12, C15, C19, C22, C28, C32, C36
was divided by the corresponding peak area of the internal standard, 13C6 -D-sorbitol.
The %RSD of the seven n-alkanes in the test samples were calculated and used to
determine reproducibility (Table 3.7). A comparison of the %RSD of the n-alkanes in
the four test volumes found that only the 25 µl and 50 µl sample volumes produced a
%RSD below the desirable 30 % RSD cut off (Edmands, Barupal and Scalbert, 2014).
The 50 µl replicate volumes produced a lower mean %RSD for the normalised nalkane values than the QC pooled samples of the same volume, however both
recorded values below 20 % RSD (Table 3.7). The 25 and 50 µl (equivalent) milk
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volumes, therefore resulted in the most reproducible measurements whereby the
internal standard would be most effective at correcting sample preparation and/or
analytical differences between samples within the greater metabolomics study. A 50
µl sample volume was used for the subsequent analysis of all study samples.
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Table 3.7

Volume (µl)

%RSD of the area ratios of 13C6 Sorbitol and Alkanes.

% RSD

% RSD (Alkanes; corrected)

(13C6 – Sorbitol;
raw peak area)

C12,

C15,

C19,

C22,

C28

C32

C36

25

12.50

7.12

6.13

6.17

6.15

5.71

5.25

10.12

50

10.56

4.40

6.24

7.53

8.91

12.82

11.79

16.50

QC (50)

20.08

15.25

14.06

12.86

12.04

14.37

15.13

17.13

75

36.62

82.20

81.05

77.91

78.99

88.15

78.91

71.62

100

40.02

59.70

58.84

59.66

59.57

57.87

60.02

61.28

Uncorrected relative standard deviations of 13C6 D-sorbitol, calculated from the raw peak areas.
Relative standard deviations of alkanes normalised to 13C6 labelled D-sorbitol.
The highlighted row indicates the %RSD recorded for the pooled QCs which were 50 µl in volume.
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3.5.2

Temperature optimisation

Derivatisation is the chemical modification of an analyte, often used to facilitate gas
chromatography. Optimisation of this technique was employed to ensure the samples
were as close to complete derivatisation as possible making them amenable to
analysis by GC-MS, while reducing the number of derivatives for a single metabolite
to achieve optimal signal intensity, and identification of the maximal number of
metabolites.

A temperature trial was conducted to determine the optimal temperature for MSTFA
derivatisation. To determine the optimal derivatisation temperature for derivatisation,
the peak area of each metabolite in a mixture of thirty metabolite reference standards
was compared, and the standard deviation between the triplicates at each of the test
temperatures calculated. The measured signal intensity (represented by peak area) is
important to the analysis and reflective of the effectiveness of the derivatisation,
however sample reproducibility (represented as standard deviation) was ultimately the
determining factor in identifying the optimal derivatisation temperature. Ideally, a
large peak area (high signal intensity) with a low standard deviation (good
reproducibility) would indicate the optimal temperature.

The methods for temperature optimisation were based on a derivatisation method by
Gummer et al. (2013) using a Thermomixer (TM) for incubation. For comparative
purpose two TM control temperatures were analysed, 37°C and 60°C, as previously
stated in 2.2.5.1.2 (derivatisation temperature optimisation). The derivatisation of
these two TM controls occurred within the microcentrifuge tubes that the metabolite
standards were prepared in. This approach was determined less suitable for incubation
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at elevated temperatures as it resulted in a greater signal of analytical artefacts (nonbiological analytes) leaching from the 2 ml polypropylene tubes.

All of the 30 measured metabolite standards were assessed for reproducibility at the
different derivatisation temperatures (Appendix 3.5a-3.4t), however those found most
relevant to the final results of this thesis are presented here (Figures 3.14-3.17). Lphenylalanine and L-methionine (Figures 3.14 and 3.16, respectively), demonstrate
the least signal reproducibility at the lowest and highest reaction temperatures. The
remaining figures are provided in Appendix 3.5a-3.4t. The optimum derivatisation
temperature varied amongst the individual reference standards, however 60°C and
75°C generally provided the strongest reproducibility in signal intensity when
incubated within the sealed analytical vial, rather than in polypropylene (Figures 3.143.17). Figure 3.14 and 3.15 display the peak area and standard deviation for
metabolite L-phenylalanine (1 TMS). Figure 3.16 and 3.17 display the peak area and
standard deviation of metabolite L-methionine (1 TMS) respectively.

L-phenylalanine (1 TMS) was the least reproducible when derivatised at 90°C and Lmethionine (1 TMS) was least reproducible at 37°C. Incubation at 90°C had the
lowest reproducibility across the entire metabolite range, followed by 37°C (37°C is
the MSTFA derivatisation temperature employed in many current protocols; Francki,
Hayton, Gummer, Rawlinson & Trengove, 2015; Gummer et al., 2013).
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Figure 3.14

Measured Peak area of L-Phenylalanine (1 TMS) using MSTFA
incubation temperatures of 37°C, 45°C, 60°C, 75°C, 90°C with the
incubation performed in a GC oven (GC) or with agitation in a
Thermomixer (TM).

Figure 3.15

Standard deviation of the measured peak area (n=3) of LPhenylalanine (1 TMS) using MSTFA incubation temperatures of
37°C, 45°C, 60°C, 75°C, 90°C with the incubation performed in a
GC oven (GC) or with agitation in a Thermomixer (TM).
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Figure 3.16

Measured peak area of L-Methionine (1 TMS) using MSTFA
incubation temperatures of 37°C, 45°C, 60°C, 75°C, 90°C with the
incubation performed in a GC oven (GC) or with agitation in a
Thermomixer (TM).

Figure 3.17

Standard deviation of the measured peak area (n=3) of LMethionine (1 TMS) using MSTFA incubation temperatures of
37°C, 45°C, 60°C, 75°C, 90°C with the incubation performed in a
GC oven (GC) or with agitation in a Thermomixer (TM).
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The derivatisation temperature with the smallest standard deviation for both LPhenylalanine (1 TMS) and L-Methionine (1 TMS) and therefore most reproducible
for these specific metabolites was 75°C as shown in Figures 3.15 and 3.17
respectively. Across the tested metabolite reference standards 75°C demonstrated the
greatest reproducibility between replicates. Where the 75°C incubation temperature
wasn’t the most reproducible, it still produced high peak intensity and a relatively low
standard deviation. Consequently, sample derivatisation was carried out at 75°C in
the later metabolomics analyses, in accordance to these findings.

3.6 Changes to the metabolite composition of human milk in response to
pain and trauma of the nipple
Untargeted metabolomics analysis was conducted on human milk samples from women
experiencing persistent nipple pain (NP) without evidence of nipple trauma (pain
subgroup; PG), or with trauma (trauma subgroup; TG) and of women not presenting
with nipple discomfort (control group; CG). Milk samples from bovine control and of
bovine animals presenting with mastitis were also assessed. A list of metabolites was
compiled and relative abundances determined to identify metabolites differing between
the TG and PG patient samples, for comparison to CG, and identify those of most
interest to this study. The use of QC samples was determined paramount to the data
integrity and used to guide the data interpretation. The QC sample was a pooled milk
sample containing all 42 milk samples both human and bovine.

The final metabolomics sample set prepared for GC-MS analysis comprised the 42
individual human and bovine milk samples, pooled milk quality controls (QC) and a
derivatisation (no milk) control. A series of conditioning solvent blanks were run at the
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start of the sequence followed by five QCs, for the purposes of conditioning the
instrument prior to milk sample analysis. Following this initial run sequence, milk
samples were randomised amongst the QC samples, with one QC analysed before and
after every four experimental samples (Figure 3.18).

Preventive instrument maintenance of the GC-MS was required during analysis of the
sample set. Due to the composition of the milk samples and non-volatile components
adhering to the inlet liner, frequent preventive GC maintenance was required.
Maintenance frequency was determined by an observed drop in signal intensity
(assessed during the sample sequence), requiring the replacement of inlet consumables
and trimming of the guard-column.

Following complete data interrogation, the QC sample results as modelled by PCA
indicated that the first 29 injections were comparable, following which the signal
intensity was noticeably poorer. Unfortunately data normalisation (to the internal
standard) and scaling were unable to correct the signal in the data acquired after this
point in the analytical sequence (as seen in the scores plot in Appendix 3.6). Therefore,
only the first 29 samples were used for the final data interpretation.

The final data set consisted of the analysis of the pooled QCs (14 replicate
preparations), five of which were analysed at the start of the GC-MS analytical
sequence (QC01-QC05), followed by one QC preceding every fourth milk sample
(which were analysed at random; QCs06-14). The QC samples were modelled by PCA
together with the experimental samples, allowing the projected clustering of the QC
samples to identify reliable measurement of the samples run amongst them. The
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projection of the scores of the first two principal components demonstrated an obvious
lack of reproducibility after sample QC_P_29 (Figure, in appendix 3.6). Subsequent
analyses could not verify if the compositional differences between samples post
QC_P_29 were biological or instrumental, therefore samples following QC_P_29 were
not used for the final interpretation.

The final sample set used for the metabolomics comparisons and interpretation included
11 control (CG), one nipple pain without trauma (PG), three nipple pain with trauma
(TG), two bovine control (BC), one bovine mastitis (BM), one bovine vat/pooled
sample (BV) and 10 QCs (Figure 13.8). Two of the human samples were collected
from the same mother (M03/N10), which were a CG and PG milk sample.
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START OF
SEQUENCE

QC01
(QC_P_01)

QC01
(QC_P_10)

M04_C04
(Hs_cont_11)

QC03
(QC_P_20)

M08_C08
(Hs_cont_21)

SEQUENCE
CUT OFF

QC02
(QC_P_02)

M02_NP05
(Hs_NT_09)

M14_C14
(Hs_cont_12)

B03_BM02
(Bt_mast_19)

M18_C18
(Hs_cont_22)

QC05
(QC_P_29)

QC03
(QC_P_03)

M22_C22
(Hs-cont_08)

M26_NP07
(Hs_T_13)

M28_NP09
(Hs_T_18)

M03_NP10
(Hs_T_23)

B09_V02
(Bt_vat_28)

QC04
(QC_P_04)

M12_C12
(Hs_cont_07)

B01_BC01
(Bt_cont_14)

M16_C16
(Hs_cont_17)

B05_BC02
(Bt_cont_24)

H03_C03
(Hs_cont_27)

QC05
(QC_P_05)

M02_C02
(Hs_cont_06)

QC02
(QC_P_15)

M06_C06
(Hs_cont_16)

QC04
(QC_P_25)

H01_C01
(Hs_cont_26)

Figure 3.18 Final metabolomic GCMS sequence run order.
Samples are labelled with their sample identification number, i.e. M02_C02 from a human participant who donated a control sample, followed
by a sequence run identification label including sample type and position in sequence, i.e. Hs_cont_06 (Hs_cont; human milk, control sample,
Hs_T; human milk, nipple pain with trauma sample, Hs_NT; human milk, nipple pain without trauma sample, QC_P; pooled quality control of
all milk samples, Bt_cont; bovine milk, control sample, Bt_mast; bovine milk, mastitis sample, Bt_vat; bovine milk, pooled sample collected from
storage vat.
101

Using the previously compiled metabolite library, the final samples were analysed
using GCMSsolutions software to compile a list of metabolites and calculated peak
areas for each analyte. Analytes measured in the no-sample-control derivatisations
were deemed analytical artefacts and removed from the data matrix, as they were
found to be of non-biological origin. The remaining features other than those of the
added analyte standards were considered metabolites endogenous to the milk samples.
The metabolite abundances were interrogated using PCA to model the variance
between the human nipple pain group and controls, together with the bovine and
pooled QC samples.

A scores plot was used as a visual tool for data mining, where the projected position of
each of the samples on the scores plot is a measure the metabolite abundances
(metabolome) relative to the metabolite abundances of the other samples on the plot.
The PCA scores plot, representing the modelling variance within the data, showed like
groupings, indicative of common features of the metabolite profiles. As anticipated,
principal component 1 (PC1), which explains 25% of the variance between test groups,
demonstrated distinct grouping of human and bovine samples with pooled QCs situated
in the middle of the two groups (Figure 3.19).
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Figure 3.19
Scores plot of PC-1 (25%) vs. PC-2 (14%) for the final sample set.
The human milk samples are indicated by the blue circle, pooled QCs by the black
circle and bovine milk samples by the red circle (Hs_cont; human milk, control sample,
Hs_T; human milk, nipple pain with trauma sample, Hs_NT; human milk, nipple pain
without trauma sample, QC_P; pooled quality control of all milk samples, Bt_cont;
bovine milk, control sample, Bt_mast; bovine milk, mastitis sample, Bt_vat; bovine
milk, pooled sample collected from storage vat).
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Samples found towards the centre of the axis indicate samples that have little influence
on the data model; in this instance the central samples are the pooled QCs as they’re an
average of the two sample sets. The samples projected with the most extreme
coordinates are the most influential in the data set relevant to principal components of
the scores plot. Therefore, it can be seen that there were markedly different groupings
for the human samples (blue circle) compared to the bovine samples (red circle), on
Figure 3.19.

Human milk samples were further analysed independent of the bovine samples and
plotted using PCA to determine any compositional variations in milk between control
mothers and those presenting with nipple pain. When plotted, the first three principal
components showed little significant grouping of test groups. However, principal
component 4 (PC4), associated with 8 % of the variance between human milk samples,
(red circles) demonstrated tentative grouping of the control and nipple pain samples
indicating possible metabolite differences consistent with the trauma state between the
two subgroups (Figure 3.20). Two samples collected from a single mother (one control:
Hs_cont_11 and one nipple pain: Hs_NT_09) are outlined by a black square. This
mother was experiencing unilateral nipple pain without evidence of trauma; the
similarity in metabolite composition between the two samples may indicate the low
severity of her condition. This result also supports that the modelled data reflects
changes to the milk composition arising out of a trauma event, rather than nipple pain
presenting without trauma.
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Figure 3.20
Score plot of PC-3 (10%) vs. PC-4 (8%) for human milk samples.
Red circles indicate nipple pain with trauma samples and the black square encloses
the two samples that were retrieved from the same mother, M03/NP10) (Hs_cont;
human milk, control sample, Hs_T; human milk, nipple pain with trauma sample,
Hs_NT; human milk, nipple pain without trauma sample.
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A loadings plot is used to visualise the influence of individual metabolites relative to
the modelled Scores projection. The metabolite position on the loadings plot indicates
its loadings value and explains its individual influence on the projected component
model. Metabolites of the most extreme values have the greatest leverage on the sample
groups as projected on the scores plot. Consistent with the Scores projection (Figure
3.20), the metabolites with the most extreme PC4 coordinates have the greatest
influence on the observed differences between trauma and no trauma groups. The
metabolites with the lowest PC4 axis coordinates (negative values) are the metabolites
most heavily associated with milk from mothers of the trauma category (TG) (Figure
3.21).

Figure 3.21

Loadings plot of PC-3 (10%) vs. PC-4 (8%) for human milk
metabolites.
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To further investigate the metabolites contributing to the projection of PC4 (found to
model differences between CG and TG samples) the correlation loadings of each
metabolite was calculated from the PCA loadings. This was to identify metabolites
most reliably contributing to the variance (Figure 3.22). The correlation loading is the
correlation between the scores and the actual observed data. The outer ellipse on the
correlation loadings plot indicates 100% of explained variance and the inner ellipse
indicates 50% of explained variance (Figure 3.22). The metabolites in the radius
between the ellipses are more discriminating for the sample set being analysed.
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Figure 3.22

Correlation loadings plot of PC-3 (10%) vs. PC-4 (8%) for human
milk metabolites.

The outer ellipse indicated 100% of explain variance and the inner ellipse indicates
50% of explained variance. Metabolites between the ellipses have the highest
influence on the data set being analysed.
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A list of the most influential metabolites based on their correlation loadings
(explained within 50-100% of the model) was constructed, as shown in Table 3.8.
Metabolites listed at the top half of the table indicate metabolites that are positively
correlated with the trauma category and have been identified to explain the variance
between TG and CG samples. Metabolites listed towards the bottom of the table
indicate metabolites positively correlated with control samples as they are found more
frequently and in larger volumes in control samples than in nipple pain samples.
Together the list of metabolites describes the most influential changes in milk
composition between the CG and TG samples.

The metabolites that displayed strong positive correlation with the TG samples in PC4
include Isoleucine 1TMS (-0.79), Unknown_29.43_1874_281 (tentative, analyte 116)
(-0.68), L-isoleucine 2TMS (-0.63), L-proline 2TMS (-0.62) and D-(+)-galactose
MEOX 29.94 1880 (-0.60) (Table 3.8).

Metabolites strongly correlated with the CG samples include Unknown_
31.54_1971_218 (0.71) and Uridine 3TMS, 38.98, 2462 (0.70) (Table 3.8).
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Table 3.8

Correlation loadings plot metabolite IDs, and axis coordinates, associated with nipple pain and control sample groups.

Sample grouping

Nipple pain
(TG)

Control
(CG)

PC4 axis coordinate
-0.79
-0.68
-0.63
-0.62
-0.60
-0.59
-0.59
-0.59
-0.58
-0.55
-0.53
-0.53
-0.52
-0.51
0.50
0.52
0.52
0.55
0.60
0.64
0.65
0.65
0.65
0.66
0.70
0.71

Data matrix ID
Isoleucine 1TMS_14.47_1186_86
Unknown_29.43_1874_281
L-Isoleucine 2TMS
L-Proline 2TMS
D-(+)-Galactose 5TMS MEOX_29.94_1880_319
Unknown_42.99_2721_204
L-Proline xTMS, 24.06, 1585_
L-Proline x TMS_24.06_585_142
Ascorbic acid, x TMS 29.67
Unknown_21.95_1484_233
B-Lactose 8TMS, 42.26
L-Methionine, 1 TMS_20.27_1416_104
3-Hydroxybutyric acid, 2 TMS_13.87_1157_86
Stearic acid 1TMS

Library Match
In house library
Wiley
Wiley
In house library
In house library
In house library
In house library
Wiley
In house library
Wiley
In house library
In house library
Wiley

Unknown_31.54_1971_218
Myristic acid 1TMS_29.3_1850_131
Propanoic acid, 2,3-bis(TMS)oxy) TMS ester
Unknown_24.98_1633_192
Silicate
L-Alanine xTMS_1894_1361
D-(+)-Glucose 5 TMS , MEOX_30.38_1924_130
Silane, trimethyl(1-methyl-1-phenylethoxy)
Oxalic acid 2TMS_13.13_1125_221
Glycine 3TMS_17.63_1308
Uridine 3TMS_38.98_2462_217
Unknown_ 31.54_1971_218

In house library
In house library
Wiley
Wiley
In house library
In house library
Wiley
In house library
In house library
In house library
In house library
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4 Discussion
Breast milk is the preferred source of nutrition for the developing infant, with
breastfeeding linked to many health, nutritional, immunological, developmental,
psychological, social, economic, and environmental benefits (Anatolitou, 2012).
Nipple pain and mastitis during the first three weeks of breastfeeding are important
clinical factors associated with early cessation of breastfeeding (Schwartz et al.,
2002). The intensity and duration of maternal nipple pain during breastfeeding have
been correlated to interference with breastfeeding and general quality of life
(McClellan et al., 2012). Women who experience pain in the first three weeks postpartum are also more likely to give up breastfeeding than women who experience pain
after the first three weeks (Schwartz et al., 2002), thus jeopardising both their own
and their infants short and long term health. Rapid identification and treatment of
these conditions would potentially reduce premature weaning and extend
breastfeeding duration. Despite initiation of breastfeeding increasing in Perth (9096% on discharge from hospital), the prevalence of breastfeeding at 6 (50-60%) and
12 months (22-28%) are still below the national targets of 80% and 40%, respectively
(Scott et al, 2006; NHRMC, 2010).

A recent Australian study recorded the incidence of nipple pain in 360 breastfeeding
women who intended to breastfeed beyond 8 weeks postpartum (Buck, Amir,
Cullinane & Donath, 2014). They found that 79% of women reported nipple pain in
the first week post partum and 58% experienced nipple damage, including cracked or
grazed nipples (Buck et al., 2014). The prevalence of nipple pain and nipple trauma
had at best reduced by half at 4 weeks post partum (43% and 24%, respectively) with
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a further decline identified at 8 weeks post partum where 20% reported nipple pain
and 8% reported nipple damage (Buck et al., 2014). In this study 20 women ceased
breastfeeding before the end of the study (>8 weeks) as a result of developing nipple
pain and trauma (Buck et al., 2014).

Despite the highest incidence of nipple pain identified in early lactation, women in the
first four weeks of lactation were deemed not acceptable for this study. This study
aimed to identify compositional changes in breast milk associated with nipple pain
and trauma. However, the composition of milk undergoes many changes over the first
three weeks post parturition until it reaches the mature phase which is maintained for
the remainder of lactation (Hassiotou & Geddes, 2013). Therefore, the composition
of milk is too variable in the initial stage of lactation to enable identification of
changes resulting from breast pathology compared to transitional changes of the milk
to mature milk. For this reason participants in this study were recruited between 1-6
months post parturition to eliminate compositional changes in the milk due to the
establishment of lactation, thereby identifying only those changes associated with
breast pathology.

The primary aim of this study was to determine compositional changes to human
milk, consequential to mothers experiencing persistent nipple pain with and without
evidence of trauma. It was hypothesized that the presence of nipple pain in lactating
women would result in changes in the human milk metabolite profile possibly due to
infection and/or inflammation of the breast, compared to asymptomatic women. A
series of bovine samples from asymptomatic cows and cows presenting with mastitis
served as comparative controls.
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The treatment for inflammatory symptoms of the breast, including nipple pain and
mastitis, has been under discussion for some time. This is largely due to the wide
spectrum of symptoms under the umbrella of ‘mastitis’, the myriad of potential
causes, and lack of international scale for the measurement of symptoms (Kvist,
Larsson, Hall-Lord, Steen & Schalen, 2008).

McClellan et al. (2012) investigated a selection of pain scales as objective measures
to compare the pain experienced by breastfeeding women. Differences in pain scale
were reported for women with nipple pain with and without evidence of trauma. Pain
scores reported for the mothers in the nipple pain with trauma group were
significantly higher than the nipple pain without trauma group (p<0.001). Mothers
experiencing nipple pain with trauma described their pain as ‘piercing’ ‘tight’ and
‘tearing’, whereas mothers in the nipple pain without trauma group most commonly
referred to their pain as ‘radiating’. In this study participants’ pain was converted to a
numerical value between 0-10; zero being no pain and 10 being the worst perceived
pain possible. Participants in the control group all reported their pain to be 0,
participants in the nipple pain group reported perceived pain levels between 4 to 10.
The mean pain level was reported for the nipple pain without evidence of trauma was
5.83 with one participant reporting pain as high as 8; however this was not different to
the TG subgroup with a mean pain score of 5.2. Compared to McClellan et al. (2012)
the trauma group was not reporting as much pain and therefore may not have been as
advanced in the mastitis continuum.

The influence of bacteria in the development of nipple pain and nipple trauma is still
not clear. Within the literature there are several studies surrounding the identification
and quantification of pathogenic bacterial species in an attempt to determine the

113

causative agents of nipple pain and mastitis. Kvist et al. (2008) conducted a bacterial
study (using PCR) to determine the role of bacteria in nipple pain and mastitis and
found five main bacterial species to be the most prevalent between control and case
samples; coagulase negative Staphylococci (CNS), viridans streptococci,
Staphylococcus aureus (S. aureus), Group B streptococci (GBS) and Enterococcus
faecalis. Despite this, viridans streptococci (OR: 1.43; p=0.04), S. aureus (OR: 1.81;
p=0.001) and GBS (OR: 2.40; p<0.001) were found significantly more often in case
samples than control. Additionally, CNS were detected significantly more often in the
milk of healthy control mothers (90%) than in those suffering from mastitis (83%)
(OR: 0.60; p=0.02) (Kvist et al., 2008). In this thesis study, CNS were found in 94%
of human milk samples and 100% of human control samples. CNS was found in
highest abundance in the human control samples (1,231 CFU/ml) compared to the
nipple pain samples (370 CFU/ml). Kvist et al. (2008) concluded that CNS was an
important bacterium in the protection against pathogens, and increasing bacterial
counts did not influence the clinical manifestation of mastitis. Furthermore, a S.
aureus study by Heikkila and Saris (2003) found that the commensal bacteria in
breast milk might inhibit the growth of S. aureus and prevent maternal breast
infections, which could explain the higher abundances in control milk samples.

The study of 346 mothers by Amir et al. (2013) using PCR found that S. aureus was
found in 82% of women presenting with nipple pain and in 79% of women without
symptoms of nipple pain or mastitis. Conversely, a microbial culture study by Rowan
et al. (2008) looking at the potential of S. aureus as a causative agent in nipple pain
and trauma found no S. aureus in their control group. Furthermore, Rowan et al.
(2008) identified S. aureus in 38% of mothers with nipple pain with minimal trauma
and no obvious infection and in 100% of the mothers presenting with nipple pain with
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obvious nipple trauma and infection. The data presented in this thesis identified no S.
aureus in the control group samples. S. aureus was positively identified in only one
nipple pain sample out of a total eleven nipple pain samples. This sample was
collected from a mother suffering from unilateral nipple pain (PG) and had 82% S.
aureus growth (620 CFU/ml) in milk from her affected breast, with no S. aureus
identified in the milk collected from her unaffected (control) breast. However, this
was the sample from a mother with nipple pain where S. aureus growth was
identified, suggesting that in this study nipple pain was not always the result of S.
aureus infection.

It should be noted that traditional microbial culture is not always a clear
representation of the microbial flora of a sample, as culture dominant species can over
grow or inhibit the growth of other species, not all species are amenable to any one
method of culture, or at all. Microorganisms isolated using standard culture
techniques are rarely the dominant and/or functionally significant species in the
communities from which they were obtained (Hugenholtz, 2002).

The study by Amir et al. (2013) found a statistically significant association between
the presence of Candida ssp. and nipple pain symptoms presenting 2-8 weeks post
partum (p=0.014). A PCR analysis of the milk of 346 lactating women found that
33% of women were positive for Candida ssp., distinctly different from the 5% of
milk samples from the same sample set that cultured positive for Candida ssp. (Amir
et al., 2013). Furthermore, control samples that tested positive for Candida ssp. at any
point were 87% more likely to develop nipple pain symptoms than mothers who
tested negative for Candida ssp. (Amir et al., 2013).
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A study by Hale et al. (2009) using microbial culture and a β-glucan assay (where βglucan concentration 80 pg/mL is considered a presumptive measure of Candida
infection) found that β-glucan was more commonly found in higher concentrations in
control samples than in symptomatic patients, although no control samples and one
symptomatic sample cultured positive for Candida (1 CFU/15 µL of milk). Hale et al
(2009) suggested that their results were the product of the extreme clean-catch
technique used for milk collection (which formed the basis for the collection method
used in this study) and that studies that draw conclusions on Candida mastitis or the
role of Candida in nipple pain may be the result of insufficient aseptic techniques and
evidence of microbial contamination through the infant’s saliva on unsterilised
nipples. Amir et al. (2013) suggested that the Hale et al. study (2009) may indicate
alternative causes of breast and nipple pain, including mechanical causes such as
infant tongue tie or bacterial infection.

A protocol similar to that of Hale et al. (2009) was used for milk collection in this
study to ensure microbial contamination of the milk, from skin flora or environmental
contaminants, did not influence the microbial composition of the milk. No fungal
species were isolated from the human samples, with nipple pain or otherwise, in this
study. Yeast species were isolated from bovine milk from both pooled vat samples
collected from a single storage vat (BV01 and BV02), but not from individual bovine
milk samples. The ability to culture yeast in pooled bovine samples showed that
Sabouraud agar was a suitable medium for the isolation of fungal species, with
evidence of only fungal species isolated by these means. Furthermore, these results
indicate that there were no fungal species in the human samples. Molecular
techniques (PCR or sequencing) would be required to confirm definitively that no
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fungal species were present in the human milk samples, or identify species nonamenable to this culture technique.

Biochemically it is possible to detect changes in certain macronutrients and
micronutrients in breast milk that are associated with closure of the tight junctions
between the lactocytes at the onset of secretory activation (Pang and Hartmann,
2007). A study by Fetherston, Lai and Hartmann (2006) found that mastitis was
associated with the reopening of the tight junctions and consequently paracellular
pathways, accompanied by increased breast permeability, inflammation of the breast,
and reduced milk synthesis. A significant increase in Na+ concentration was observed
in women with nipple trauma (p<0.004), and a further increase in mean Na+
concentration was observed in women with clinical mastitis (21.8 mmol/L)
(Fetherston et al., 2006). In this thesis, a significant difference in Na+ concentration
was observed between mothers in the control and TG groups (p<0.001). However, the
mean Na+ concentration for the TG subgroup (8.04 ± 2.40 mM) was much lower than
that observed in women with mastitis in the Fetherston et al. study (2006), indicating
that no participant in the study had mastitis, but possibly had the potential to develop
into mastitis if left untreated.

The composition of milk is highly variable over the course of lactation, between feeds
and between mothers (Chung, 2014) and can be influenced by maternal and infant
health and medication use (McManaman & Neville, 2003). Paracellular pathways
allow the direct exchange of interstitial or serum substances into the milk. This
transport pathway closes during the initiation of lactation, due to the reduction of tight
junctions between the epithelial cells (McManaman & Neville, 2003). This pathway is
affected by the physiological state of the breast, and during an episode of
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inflammation or mastitis, tight junctions between the epithelial cells can become
compromised, allowing plasma components such as sodium and calcium to leak into
the milk (Shennan & Peaker, 2000).

Assessment of the increased permeability of the paracellular pathway can be
determined by measuring the solute content of the milk, in particular Na+ and K+
(Shennan & Peaker, 2000). Damage to the paracellular pathway can be identified by
an increase in Na+ concentration and decrease in K+ concentration. However,
measurement of the Na+/K+ ratio has been proposed as a more accurate indicator as it
reduces the influence of individual differences due to the large variation in human
milk composition between individuals. Areetey et al. (2008) proposed an elevated
Na+/K+ ratio above 1.0 to be considered indicative of infection.

No individual in this study recorded a Na+/K+ ratio above one. The highest ratio was
0.811 recorded from the milk of a mother experiencing persistent nipple pain with
trauma. The TG subgroup had a significantly higher ratio than the control group
(p<0.001) and a mean ratio difference of 0.13 between the TG and PG nipple pain
subgroups indicating, alike the pain scores, little difference between the groups.

Sodium and potassium analysis has been found to be a useful tool in relation to
mastitis, however it appears less conclusive in the analysis of nipple pain. Mastitis can
cause a significant amount of damage to mammary tissue, resulting in considerable
alteration in milk composition. As nipple pain without incidence of mastitis is often
less invasive, it is possible that the damage to the mammary tissue was not extensive
enough to result in a significant increase in Na+/K+ concentration or ratio in this study.
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All analyses of sodium and potassium concentrations presented here should be treated
with caution, as the sample size can be considered too small to draw definitive
conclusions. This is due to the pre-expected marginal differences between the groups
due to the subtleties of the pain condition. To detect a true difference in Na+/K+ ratio
between nipple pain samples in TG and PG subgroups, a larger sample size would be
required. Using the independent nipple pain samples from this study, a t-test power
calculator was used to determine the sample size required to improve the power of the
study to 80 and 90% (Lenth, 2009). The two-sample group t-test found that an
increase in sample size to 20 participants per group would be required to increase the
power of the study to 80% and 26 participants per group would increase the power of
the study to 90% (Lenth, 2009). It is assumed that each participant would be included
in only one group, and that only one sample would be taken from each. If more
samples were taken, or another study design was used, then smaller numbers might be
appropriate.

The burgeoning area of metabolomics as a diagnostic medium has begun to be
explored in the dairy industry. A metabolomics study by Sundekilde et al. (2013)
identified a series of metabolite biomarkers including isoleucine, lactate, butyrate and
acetate to be linked with an elevated somatic cell count in bovine milk, which is
indicative of mastitis. Sundekilde et al. (2013) proposed that the detection of these
biomarkers could be used to determine milk quality, diagnose mastitis and to
determine the level of infection. The same concept could be applied to human milk:
determining changes to metabolited as a means of diagnosis for breast complications.
Metabolite profiling has the potential to illuminate how the presence of infection and
inflammation affects breast milk composition, leading to a greater understanding of
the effect of nipple pain and mastitis on the lactating breast and providing a means of
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monitoring treatment. As nipple pain is often a precursor to mastitis, it is important to
understand if underlying breast pathology exists. Consequently, if the severity of
nipple trauma is associated with underlying infection, then profiling the metabolome
of expressed milk will identify any differences in metabolite composition between
mothers experiencing varying degrees of pain and discomfort.

Although there have been some studies that associate certain species of bacteria with
incidences of nipple pain and mastitis, there is still no reliable diagnostic biomarker of
pain or infection to enable rapid effective treatment. Metabolomics is widely used as a
functional tool in biomarker detection and systems biology. Metabolomics involves
the unbiased quantitative and/or qualitative analysis of the complete set of metabolites
present in a biological system. Biostatistics plays an essential role in analysing
differences in metabolomes and enabling the identification of metabolites pertinent to
a particular phenotypic characteristic (Koek, Jellema, van der Greef, Tas &
Hankemeier, 2011).

Generally a non-targeted metabolomics approach is used to gain new insights and a
better understanding of the biological functioning of a cell or organism in an attempt
to interpret biological outcomes (Koek et al., 2011). It is crucial that all steps of the
analytical method, namely sample preparation, data acquisition and data processing,
are addressed when determining a suitable experimental design. Optimisation,
validation and quality control of analytical methods are of the highest importance
(Koek et al., 2011).

Optimisation of sample preparation, namely sample volume, was important to identify
the dynamic range in metabolite concentrations that would allow the unbiased
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measurement of sample components for any given instrumental analysis. The
optimisation of the sample loading on the GC was required to determine an
amount/mass of metabolite extract that would not overload the instrument while still
being large enough to identify metabolites present at low abundance. Milk sample
volumes of 25 µl, 50 µl, 75 µl and 100 µl were analysed with the addition of an
internal standard (13C6 labelled D-sorbitol) to determine reproducibility and to assess
the capacity for this internal standard to reliably correct for changes in signal intensity
across data from GC-MS acquisition.

Extraction and derivatisation efficiency can be estimated using labeled n-alkanes as
reference compounds and comparing their response to the response of derivatised
metabolites (Koek, Muilwijk, van der Werf, & Hankemeier, 2006). In this instance we
sought to assess the reproducibility of the peak intensity of a series of n-alkane
analytical standards (C12, C15, C19, C22, C28, C32, C36) added to derivatised milk
extracts of differing concentration and the capacity for the corresponding peak area of
the internal standard, 13C6 labelled D-sorbitol, to correct for differences in analytical
reproducibility among a sample set. The %RSD of the alkanes was used to determine
the reproducibility of the four test volumes. Food and Drug Administration guidelines
(FDA) for biomarker studies specify a RSD of < 20% to be an acceptable level of
precision (Kirwan et al., 2013). The dried 50 µl milk volume metabolite extract was
the largest sample volume that could be dissolved in a single derivatising volume
while maintaining reproducibility of the added compounds (alkanes) below a %RSD
of 30. Larger sample volumes may be compromised due to inadequate amounts of
TMS reagent for complete derivatisation, a factor of milk being a complex biological
matrix, as well as potential interference with deconvolution and therefore accuracy in
measurement of peak areas. In order to not compromise the measurement of the
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lower abundant metabolites, the largest reproducible volume, 50 µl, was used for
subsequent metabolomics analyses.

Many metabolites contain polar functional groups, and are thermally unstable at the
temperatures required for injection into a GC or are simply not volatile. Derivatisation
prior to GC analysis is often needed to extend the application range of GC based
methods (Koek et al., 2011). The majority of GC-based metabolomics methods are
based on derivatisation using an oximation reagent followed by silylation (often by
MSTFA), or solely silylation (Gullberg et al., 2004; Jonnson et al., 2006; Zhang,
Wang, Du, Zhu & A, 2007).

Koek et al. (2006) tested several derivatisation reagents including BSTFA, MSTFA,
MSTFA with 1% TMCS, BSA, TMSI and TMSI/BSA/TMCS 3:3:2, and found the
highest recoveries and smallest RSDs were found using MSTFA. Within the literature
a range of derivatisation temperatures has been tested. Gullberg et al. (2004) trialled
MSTFA derivatisation at 20°C, 40°C and 60°C and found that 60°C was the optimal
temperature. Dunn et al. (2011) used rapid derivatisation at 80°C. Gummer et al.
(2013) used 37 °C for MSTFA derivatisation. Bressanello et al. (2014) incubated at
100°C following the addition of MSTFA.

For this study a range of derivatisation temperatures were assessed to determine the
optimal derivatisation temperature. Samples were prepared using methoxymation
followed by MSTFA derivatisation incubated at 37°C, 45°C, 60°C, 75°C and 90°C.
Depending on the target metabolites, different analytical approaches are required and
different requirements are posed on analytical performance, including detection
limits, accuracy of compound identification and reproducibility (Koek et al., 2011). In
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this instance, reproducibility is of the upmost importance due the already highly
variability of human milk composition between individuals.

Analysis of the tested derivatisation temperatures found that incubation at 75 °C
resulted in high signal intensity, but more importantly the highest reproducibility
(determined by comparison of standard deviation across the three replicates for each
of the test temperatures). The reliability and suitability of sample preparation, data
acquisition, data preprocessing and data analysis are imperative for accurate
biological interpretation (Koek at al., 2011).

Metabolomics revolves around the central concept that an individual’s metabolic state
is a close representation of his/her current physiological state (Fanos et al., 2012).
Analysis of an individual’s metabolome is indicative of their current heath and
disease status (Fanos et al., 2012). Here, we used a metabolomics analysis of human
milk from control mothers, and mothers experiencing persistent nipple pain with or
without evidence of trauma, to identify metabolite difference reflective of underlying
physiological breast health.

Due to the large variation in breast milk composition between individuals,
irrespective of their health status, it was important to ensure appropriate quality
controls and internal standards were used in the metabolomics analysis to account for
noise within the data and identify true biological variation between the control and
nipple pain subgroups. Using only a single internal standard for purpose of
normalisation can also be presumptuous in that it assumes that all metabolites in a
sample are subject to the same amount of unwanted or external variation, often failing
to remove unwanted factors (De Livera et al., 2012). In this case a labelled internal

123

standard, 13C6 labelled D-sorbitol, with the addition of pooled QCs, a mixture of the
entire sample set under study, were used to normalise and interrogate the data. A
labelled or synthetic internal standard prevents variation resulting from chemical
properties and confusion of the internal standard with metabolites of interest that may
co-elute or appear similar in structure (De Livera et al., 2012). The use of multiple
internal standards or similar, the use of pooled QCs for example, has been found to be
more effective at removing unwanted instrumental interference and leads to lower
variability of the normalised metabolite abundances (De Livera et al., 2012).
Normalisation allows the reduction of variation or interference between sample
extraction efficiency and instrumentation. Resulting values can then be scaled to the
median intensity (as opposed to mean; which has been found to be less effective) for
each metabolite across the data set (Veselkov et al., 2011). The data manipulation
employed in this thesis was to reduce the influence of the highest abundant
metabolites within the model by reducing the range of dynamic abundance and
therefore the bias within the raw data. A log scaling approach was also used as an
additional level of scaling for data modelling (Veselkov et al., 2011). Additionally
within this thesis, PCA was used for quality control purposes and initially focused on
the pooled milk (quality control) samples, which were run at regular intervals between
samples throughout data acquisition.

It is known that the first few injections of samples on the instrument show variability
and give unrepresentative results within metabolomics analyses due to small changes
in signal intensity and retention time (Veselkov et al., 2011). For this reason, the
column was ‘conditioned’ using five injections of the same biological matrix as the
sample set, in this case pooled QC samples, to reduce this initial variability between
sample replicates.
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The ion source of the MS can become contaminated, especially when using
metabolite dense biological matrices such as human and bovine milk, resulting in a
gradual decline in instrument sensitivity over time (Veselkov et al., 2011). A slow
degradation of signal intensity was observed over the duration of analysis within this
study despite preventive cleaning of the ion source and regular monitoring and
maintenance of GC consumables. Internal standards and QCs were unable to correct
for instrumental error and decline in signal intensity. This indicated that the observed
decline in signal intensity was not uniform across the chromatogram and could
unlikely be corrected. As a consequence any samples analysed within the analytical
sequence amongst the QC samples that failed to group by PCA were determined as
not meeting the requirements of the quality control and were excluded from the final
interpretation.

Within the sample data, the PCA showed that the first three principal components
exhibited little significant grouping of the human nipple pain groups. PC-4, associated
with 8% of the variance between the human milk and samples, best showed difference
in metabolite composition between the control and trauma samples. Whilst ideally the
first components of a PCA would distinguish sample groupings consistent with the
study design, the result of finding PC4 of most relevance was not entirely unexpected
due to the subtlety of the condition under study (nipple pain) as demonstrated
throughout this thesis, such as in the Na+/K+ results, and the inherent variation in milk
composition between individuals and within individuals over time (Grote et al.,
2015).
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The projected position of each of the samples on the scores plot (Figure 3.19) is a
measure of their individual metabolite abundances relative to the metabolite
abundances of the other samples on the plot. Samples found close to each other on the
scores plot indicate high positive correlation. This can be seen with Hs_cont_6 (C02)
and Hs_NT_09 (NP05), which are closer to each other on the scores plot than other
samples, indicated by the black square in Figure 3.19. These samples were retrieved
from a single mother (M03) who donated both a control and nipple pain sample. The
mother was suffering from unilateral nipple pain with no evidence of trauma and had a
Na+/K+ ratio of 0.54 (where a ratio above 1 is considered indicative of infection) with
no evidence of pathogenic bacteria in her milk, it is therefore consistent that these
samples are compositionally similar. In contrast, samples located in diagonally opposite
quadrants have a tendency to be negatively correlated, indicating a compositional
difference between nipple pain with trauma samples (Hs_T_13, Hs_T_18 and
Hs_T_23) located at the bottom of the scores plot, with a negative PC-4 score
coordinate, and the control samples present in the opposite quadrants, with a positive
PC-4 score coordinate (Figure 7.7). Additionally, the trauma samples recorded the
highest Na+/K+ ratio; of note was sample Hs_T_13 (NP07), which had the highest ratio
of 0.81, a measurement used as an indication of breast trauma resulting in reopening of
paracellular pathways in the mammary tissue (Aryeetey et al., 2008).

The correlation loadings plot (Figure 3.20) displays all of the measured metabolites
from the human milk and was used to identify which metabolites were able to
constitute to the variance between the human sample set as well as identify metabolites
that are positively and negatively correlated with control and nipple pain samples.
Metabolites found closer to the middle of the plot do not contain enough structured
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variance and cannot be explained by the plot. These were determined inconsequential
to a nipple trauma event.

Amino acids, in particular isoleucine and proline, were amongst the metabolites found
most positively correlated with human trauma samples. Within the literature there are
several studies that have identified a link between an increase in amino acid
concentration in response to inflammatory diseases including osteoarthritis, Crohn’s
disease and inflammatory bowel conditions. Alteration in tissue concentration of amino
acids is likely the result of gross tissue destruction or cellular apoptosis (Fitzpatrick &
Young, 2013).

A study by Marchesi et al. (2007) of faecal matter from healthy participants and
participants with Crohn’s disease and ulcerative colitis found a significantly higher
quantity of amino acids in participants with inflammatory bowel conditions. An
increase in isoleucine concentration (+ 0.69) was observed in the faecal matter of
patients with Crohn’s when compared to control samples (Marchesi et al., 2007). Other
amino acids showing increases included leucine, alanine, lysine and valine. A study by
Zhai et al. (2010) of serum from patients with osteoarthritis found an increase in amino
acids, in particular valine and leucine, in test patients compared to controls.
Additionally Griffin et al. (2004) used an adenoviral vector to induce a focal
inflammatory lesion in rats and identified an increase in urinary amino acids, including
leucine, isoleucine and valine, in response to tissue inflammation.

Examples relating to bovine milk also exist in the literature. Sundekilde et al. (2013)
profiled bovine milk from cows with mastitis to identify metabolites associated with
increased somatic cell count. Again, isoleucine was positively correlated with an
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increased somatic cell count and a significant difference was found between healthy
cows and cows with mastitis (p=0.014). A preliminary bovine study by Ianni et al.
(2015) profiled selective amino acids in milk from cows with sub-clinical and clinical
mastitis to identify metabolite differences in milk from cows with varying levels of
mastitis. This study found that amino acids, aspartic acid, isoleucine and valine were
only detectable in the milk from cows with clinical mastitis and not in the sub clinical
mastitis milk samples (Ianni et al., 2015). Consequently, it was proposed that these
three potential biomarkers could be useful for the confident identification of clinical
mastitis in cases that are difficult to diagnose (Ianni et al., 2015). Similarly the
measured increase in amino acids in breast milk presented in this thesis may serve as an
indication of inflammation and damage to mammary tissue including paracellular
pathways.

Due to the small sample numbers resulting from technical problems and instrumental
error, we are unable to conclude complete significance of these results. However, the
conditions determined and the data provide promising direction for future
metabolomics studies. Metabolomics offers opportunities for further refinement of
these presented analyses and potential application for more complete human milk
analysis if complementary techniques together with the GC-MS analyses presented
here were to be combined for a more complete understanding of the milk metabolome.
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5 Conclusion
Nipple pain is a common problem for breastfeeding mothers in Australia and often
persists for several weeks post partum. As a result it is largely responsible for
cessation of breastfeeding in early lactation (weeks 1-4), which can adversely affect
the developing infant. It is important to establish the effect of nipple pain and trauma
on breast health via breast milk composition, which would then enable rapid diagnosis
of pathology, timely intervention and appropriate monitoring of treatment.

In this study microbial analysis of the milk of mothers with nipple pain found limited
numbers of potentially pathogenic bacteria, therefore participants were unlikely to
have subclinical mastitis, which is reflected also in the pain scores and Na+/K+ ratios.
However, GC-MS analysis identified differences in metabolite composition between
the human control and nipple pain groups. A series of amino acids, previously found
to be associated with inflammatory conditions, was elevated in nipple pain milk
samples, suggesting that indeed metabolomics may potentially identify mothers with
nipple pain that might be predisposed to infection. Consequently, if severity of trauma
is related to an underlying infection, then profiling the metabolites may lead to
identification of differences in the metabolite composition between mothers'.

Future analysis of human milk should employ LC-MS for analysis of the non-polar
fraction of the milk to further the understanding of the milk metabolome. Following
the optimisation of an untargeted metabolomics approach, a targeted analysis for the
identification of bacterial and fungal metabolites will also increase the potential for
diagnosis and provide insight into the breast microbiome.
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In conclusion, these results provide preliminary support to confirm the concept that
milk expressed by mothers presenting with nipple pain contain compositional
differences, detected by metabolomics, which may be related to the early stages of the
continuum of mastitis. Further study is required on much larger sample sets to
determine the efficacy of this technique in the detection of breast infection and the
relationship between compositional change and severity of infection.
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Appendices
Appendix 2.1 Consent form provided to all participants prior to milk collection.

Biochemistry and Molecular Biology
School of Biomedical, Biomolecular and Chemical
Sciences

M310, The University of Western Australia
35 Stirling Highway
CRAWLEY WA 6009
Prof. Peter E. Hartmann
Telephone: +61 (0)8 6488 3327
Facsimile: +61 (0)8 6488 1148
Email: hartmanp@cylllene.uwa.edu.au

Breastfeeding Centre of Western Australia:
Agnes Walsh House
King Edward Memorial Hospital for Women
Bagot Road
SUBIACO WA 6008
Telephone +61 (0)8 9340 1846

Composition of human milk
Consent Form
This study aims to learn more about the composition of human milk and the changes in
concentration during the day and throughout lactation, and possible contaminants.
I
FAMILY NAME

GIVEN NAMES

have read the information sheet about this study and any questions I have asked have been
answered to my satisfaction. I agree to participate in this activity, realising that I may
withdraw at any time without reason and without prejudice.
I understand that all information provided is treated as strictly confidential and will not be
released by the investigator unless required to do so by law.
I have been advised as to what data is being collected, what the purpose is, and what will be
done with the data upon completion of the research.
I agree that research data gathered for the study may be published provided my name or other
identifying information is not used.
_______________________________________ _____________________
Participant
Date
The Human Research Ethics Committee at the University of Western Australia requires that
all participants are informed that, if they have any complaint regarding the manner, in which a
research project is conducted, it may be given to the researcher or, alternatively to the
Secretary, Human Research Ethics Committee, Registrar’s Office, The University of Western
Australia, 35 Stirling Highway, Crawley, WA 6009 (telephone number 6488-3703). All study
participants will be provided with a copy of the Information Sheet and Consent Form for their
personal records.
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Appendix 2.2. General information sheet provided to all participants prior milk
collection.
Have you previously participated in a
study with the Hartmann Human Lactation
Research Group?
First Name
Last Name
DOB Baby (dd/mm/yy)
DOB mother (dd/mm/yy)
Email
Phone/Mobile
Address
Number of Children
Have you done a HIV and Hepatitis
check?
If you have other children, did you
breastfeed any of them? If yes, for how
long?
General Healthy Status of mother/baby
(presence of nipple pain trauma/no trauma)

Current Medication

Visual Analogue Scale (pain intensity during breastfeeding)
No pain

Worst Pain Imaginable
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Appendix 2.3. Online questionnaire which participants were asked to fill out
following milk ample collection.
Retrieved from: https://breastfeeding.bcs.uwa.edu.au
Section A
Date of Birth
Last year of completed education
Further completed education
Marital Status
Number of Children
Ethnic Group
Height and Weight
Left or Right handed
Section B
Bra Size before pregnancy
Current Bra Size
Breast Piercing
Did you smoke during pregnancy?
Do you smoke now?
List of experienced problems:
High Blood Pressure
Gestational Diabetes
Antenatal Bleeding
Postpartum Haemorrhage
Depression
Hospitalisation for any reason
Current medications
Allergies
Section C
Infant Gender
Infant Date of Birth
Gestational Weeks and Days
Birth Weight
Birth Length
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Birth Apgar Scores
Mode of Delivery
Drugs during delivery
Was the baby admitted to special Care nursery?
Special Care Nursery Details?
Baby's allergies
Baby's current medications
Time before baby's first feed
Day milk came in
Baby feed method
Intended baby feed length
Baby's weight at 6 weeks
Baby's dummy usage
Breastfeeding relationship concerns
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Appendix 3.1. Human sample demographic data.
Mother Age

Infant Age

AB

Pain

(Years)

(Weeks)

(Y/N)

(1-10)

N/A

23.65

11.9

1

N

0

NP-No Trauma

Control

29.15

5.9

1

N

8

C03/NP10

NP-Trauma

Control

31.7

5.7

1

Y

6

M04

C04

Control

N/A

28.39

15.7

2

N

0

M05

C05

Control

N/A

25.78

8.3

2

N

0

M06

C06

N/A

Control

32.84

16.3

3

N

0

M07

C07

Control

N/A

30.87

17.7

2

N

0

M08

C08

Control

N/A

29.84

21.1

1

N

0

M09

C09

Control

N/A

30.72

25.6

2

N

0

M10

C10

N/A

Control

40.2

25.7

1

N

0

M11

C11

Control

N/A

34.35

26.1

2

N

0

M12

C12

Control

N/A

34.34

10.7

3

N

0

M13

C13

Control

N/A

22.59

19.7

2

N

0

M14

C14

N/A

Control

35.06

17.4

2

N

0

M15

C15

Control

N/A

32.8

22.7

1

N

0

M16

C16

Control

N/A

33.28

22.3

1

N

0

Participant ID

Group ID

Right Breast

Left Breast

M01

C01

Control

M02

C02/NP05

M03

Parity

ix

M17

C17

N/A

Control

40.8

14

3

N

0

M18

C18/NP02

NP-No Trauma

Control

28.06

10.4

1

N

10

M19

C19

Control

N/A

22.19

5

2

N

0

M20

C20

N/A

Control

31.26

7.6

2

N

0

M21

C21

Control

N/A

24.18

7.1

1

N

0

M22

C22/NP06

Control

NP-No Trauma

34.82

7.1

1

N

2

M23

NP01

NP-No Trauma

N/A

28.94

21.6

1

N

4

M24

NP03

N/A

NP-No Trauma

40.43

6.9

1

N

3

M25

NP04

NP-No Trauma

N/A

39.18

6.9

4

N

8

M26

NP07

NP-Trauma

N/A

37.11

5.1

2

N

5

M27

NP08

NP-Trauma

N/A

35.87

4.6

2

N

4

M28

NP09

NP-Trauma

N/A

29.5

7

2

N

7

M29

NP11

NP-Trauma

N/A

34.79

22.7

2

N

4

Highlighted rows indicate participants who were suffering from unilateral nipple pain and provided a control and nipple pain sample.
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Appendix 3.3. CFU counts for blood agar cultures of human milk samples and
individual and pooled vat bovine milk samples.
Participant ID

Sample ID

Group

CFU/ml

M01

C01

Control

500

M02*

C02

Control

2670

M03*

C03

Control

0

M04

C04

Control

1050

M05

C05

Control

300

M06

C06

Control

18680

M07

C07

Control

50

M08

C08

Control

10

M09

C09

Control

760

M10

C10

Control

80

M11

C11

Control

70

M12

C12

Control

10

M13

C13

Control

70

M14

C14

Control

50

M15

C15

Control

500

M16

C16

Control

400

M17

C17

Control

310

M18*

C18

Control

2500

M19

C19

Control

130

M20

C20

Control

6750

M21

C21

Control

500

M22*

C22

Control

320

M23

NP01

Pain- No Trauma

20

M18*

NP02

Pain- No Trauma

760

M24

NP03

Pain- No Trauma

580

M25

NP04

Pain- No Trauma

690

M02*

NP05

Pain- No Trauma

380

M22*

NP06

Pain- No Trauma

210

M26

NP07

Pain- Trauma

110

M27

NP08

Pain- Trauma

450

ix

M28

NP09

Pain- Trauma

990

M03*

NP10

Pain- Trauma

12000

M29

NP11

Pain- Trauma

340

B01

BC01

Control

410

B01

BM01

Mastitis (Untreated)

330

B01

BM02

Mastitis (Untreated)

1010

B02

BM03

Mastitis (Treated)

1400

B02

BC02

Control

20

B03

BC03

Control (Colostrum)

30

B04

BM04

Mastitis (Untreated)

50

V01

BV01

VAT 1

4630

V02

BV02

VAT 2

4330

(*) Indicates paired samples for human participants who donated both a control and
nipple pain sample.
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Appendix 3.4. Complete Na+/K+ data set.
Participant ID Sample ID

Group

Na+

K+

(mM)

(mM)

Na+/K+ Ratio

M01

C01

Control

6.490

12.416

0.523

M02*

C02

Control

5.744

14.403

0.399

M03*

C03

Control

4.073

13.461

0.303

M04

C04

Control

4.555

11.757

0.387

M05

C05

Control

7.138

12.635

0.565

M06

C06

Control

5.126

13.431

0.382

M07

C07

Control

4.699

13.199

0.356

M08

C08

Control

4.407

12.553

0.351

M09

C09

Control

3.613

11.108

0.325

M10

C10

Control

3.948

13.379

0.295

M11

C11

Control

4.918

13.579

0.362

M12

C12

Control

4.490

13.608

0.330

M13

C13

Control

3.933

12.858

0.306

M14

C14

Control

4.593

11.886

0.386

M15

C15

Control

5.222

15.013

0.348

M16

C16

Control

2.541

10.047

0.253

M17

C17

Control

3.204

12.443

0.257

M18*

C18

Control

3.613

10.541

0.343

M19

C19

Control

3.990

13.274

0.301

M20

C20

Control

3.409

11.527

0.296

M21

C21

Control

2.698

14.275

0.189

M22*

C22

Control

2.621

12.447

0.211

M23

NP01

Pain- No Trauma

3.641

11.217

0.325

M18*

NP02

Pain- No Trauma

4.809

13.466

0.357

M24

NP03

Pain- No Trauma

6.068

14.179

0.428

M25

NP04

Pain- No Trauma

9.212

16.552

0.557

M02*

NP05

Pain- No Trauma

4.720

14.332

0.329

M22*

NP06

Pain- No Trauma

6.392

11.527

0.555

M26

NP07

Pain- Trauma

11.528

14.209

0.811

M27

NP08

Pain- Trauma

7.032

14.580

0.482

ix

M28

NP09

Pain- Trauma

7.300

14.301

0.510

M03*

NP10

Pain- Trauma

9.136

16.875

0.541

M29

NP11

Pain- Trauma

5.204

12.277

0.424

B01

BC01

Control

19.779

21.011

0.941

B01

BM01

Mastitis (Untreated)

45.482

12.789

3.556

B01

BM02

Mastitis (Untreated)

29.776

17.654

1.687

B02

BM03

Mastitis (Treated)

26.562

20.432

1.300

B02

BC02

Control

8.442

25.495

0.331

B03

BC03

Control (Colostrum)

22.357

24.527

0.912

B04

BM04

Mastitis (Untreated)

19.213

25.440

0.755

V01

BV01

VAT 1

11.528

24.058

0.479

V02

BV02

VAT 2

11.552

24.370

0.474

* Indicate mothers that have given both a control and nipple pain sample
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Appendix 3.5a Measured peak area of L-Methionine (1 TMS) MSTFA
incubation temperatures of 37°C, 45°C, 60°C, 75°C, 90°C with the incubation
performed in a GC oven (GC) or with agitation in a Thermomixer (TM).

Appendix 3.5b Standard deviation of the measured peak area (n=3) LMethionine (1 TMS) using MSTFA incubation temperatures of 37°C, 45°C, 60°C,
75°C, 90°C with the incubation performed in a GC oven (GC) or with agitation
in a Thermomixer (TM).

ix

Appendix 3.5c Measured peak area of Aspartic acid (2 TMS) using MSTFA
incubation temperatures of 37°C, 45°C, 60°C, 75°C, 90°C with the incubation
performed in a GC oven (GC) or with agitation in a Thermomixer (TM).

Appendix 3.5d Standard deviation of the measured peak (n=3) of Aspartic acid
(2 TMS) using MSTFA incubation temperatures of 37°C, 45°C, 60°C, 75°C, 90°C
with the incubation performed in a GC oven (GC) or with agitation in a
Thermomixer (TM).
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Appendix 3.5e Measured peak area of Mix N Unknown 1 using MSTFA
incubation temperatures of 37°C, 45°C, 60°C, 75°C, 90°C with the incubation
performed in a GC oven (GC) or with agitation in a Thermomixer (TM).

Appendix 3.5f Standard deviation of the measured peak area (n=3) of Mix N
Unknown 1 using MSTFA incubation temperatures of 37°C, 45°C, 60°C, 75°C,
90°C with the incubation performed in a GC oven (GC) or with agitation in a
Thermomixer (TM).
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Appendix 3.5g Measured peak area of Ribitol (5 TMS) using MSTFA incubation
temperatures of 37°C, 45°C, 60°C, 75°C, 90°C with the incubation performed in a
GC oven (GC) or with agitation in a Thermomixer (TM).

Appendix 3.5h Standard deviation of the measured peak area (n=3) of Ribitol (5
TMS) using MSTFA incubation temperatures of 37°C, 45°C, 60°C, 75°C, 90°C
with the incubation performed in a GC oven (GC) or with agitation in a
Thermomixer (TM).
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Appendix 3.5i Measured peak area of Mannitol (6 TMS) using MSTFA
incubation temperatures of 37°C, 45°C, 60°C, 75°C, 90°C with the incubation
performed in a GC oven (GC) or with agitation in a Thermomixer (TM).

Appendix 3.5j Standard deviation of the measured peak area (n=3) of Mannitol
(6 TMS) using MSTFA incubation temperatures of 37°C, 45°C, 60°C, 75°C, 90°C
with the incubation performed in a GC oven (GC) or with agitation in a
Thermomixer (TM).
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Appendix 3.5k Measured peak area of D(-)-Fructose (5 TMS, 1 MEOX) using
MSTFA incubation temperatures of 37°C, 45°C, 60°C, 75°C, 90°C with the
incubation performed in a GC oven (GC) or with agitation in a Thermomixer
(TM).

Appendix 3.5l Standard deviation of the measured peak area (n=3) of D(-)Fructose (5 TMS, 1 MEOX) using MSTFA incubation temperatures of 37°C,
45°C, 60°C, 75°C, 90°C with the incubation performed in a GC oven (GC) or
with agitation in a Thermomixer (TM).
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Appendix 3.5m Measured peak area of Citric acid (4 TMS) using MSTFA
incubation temperatures of 37°C, 45°C, 60°C, 75°C, 90°C with the incubation
performed in a GC oven (GC) or with agitation in a Thermomixer (TM).

Appendix 3.5n Standard deviation of the measured peak area (n=3) of Citric
acid (4 TMS) using MSTFA incubation temperatures of 37°C, 45°C, 60°C, 75°C,
90°C with the incubation performed in a GC oven (GC) or with agitation in a
Thermomixer (TM).
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Appendix 3.5o Measured peak area of Putrescine using MSTFA incubation
temperatures of 37°C, 45°C, 60°C, 75°C, 90°C with the incubation performed in a
GC oven (GC) or with agitation in a Thermomixer (TM).

Appendix 3.5p Standard deviation of the measured peak area (n=3) of Putrescine
using MSTFA incubation temperatures of 37°C, 45°C, 60°C, 75°C, 90°C with the
incubation performed in a GC oven (GC) or with agitation in a Thermomixer
(TM).
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Appendix 3.5q Measured peak area of Sorbitol (5 TMS) using MSTFA
incubation temperatures of 37°C, 45°C, 60°C, 75°C, 90°C with the incubation
performed in a GC oven (GC) or with agitation in a Thermomixer (TM).

Appendix 3.5r Standard deviation of the measured peak area (n=3) of Sorbitol (5
TMS) using MSTFA incubation temperatures of 37°C, 45°C, 60°C, 75°C, 90°C
with the incubation performed in a GC oven (GC) or with agitation in a
Thermomixer (TM).
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Appendix 3.5s Measured peak area of Myo-insositol (6 TMS) using MSTFA
incubation temperatures of 37°C, 45°C, 60°C, 75°C, 90°C with the incubation
performed in a GC oven (GC) or with agitation in a Thermomixer (TM).

Appendix 3.5t Standard deviation of the measured peak area (n=3) of Myoinsositol (6 TMS) using MSTFA incubation temperatures of 37°C, 45°C, 60°C,
75°C, 90°C with the incubation performed in a GC oven (GC) or with agitation
in a Thermomixer (TM).
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Appendix 3.6 Scores plot of PC-1 (18%) vs. PC-2 (11%) illustrating the
reproducibility of the pooled quality controls

The black circle indicates the cluster of QCs with comparatively lower variance; the
red circles indicate where variation in QCs is introduced by instrumental
maintenance cycles.
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